<html xmlns="http://www.w3.org/1999/xhtml">

<body>
    <div xmlns="" class="article" name="OPT_ID_1">
        <div class="item-info hide" name="OPT_ID_2">
            <div class="jid" name="OPT_ID_3">YJINF</div>
            <div class="aid" name="OPT_ID_4">3080</div>
            <div class="ce_pii" name="OPT_ID_5">S0163-4453(13)00067-4</div>
            <div class="doi" name="OPT_ID_6"><span class="x">DOI:&#160;http://dx.doi.org/</span>10.1016/j.jinf.2013.03.011</div>
            <div class="ce_copyright" name="OPT_ID_7"></div>
        </div>
        <div class="head" name="OPT_ID_776">
            <div class="ce_title" id="title0010" name="OPT_ID_777">Usefulness of IgM-specific enzyme immunoassays for serodiagnosis of syphilis: Comparative evaluation of three different assays</div>
            <div class="ce_author-group" id="authorgroup" name="OPT_ID_778"><span name="LQ1"></span>
                <div class="ce_author" id="au1" name="OPT_ID_779"><span class="ce_given-name" name="OPT_ID_780" title="given name">Philipp P.<span class="x">&#160;</span></span><span class="ce_surname" name="OPT_ID_781" title="surname">Bosshard</span><a title="cor1" class="ce_cross-ref" style="color:blue" name="OPT_ID_782"><span class="ce_sup" name="OPT_ID_783"><span class="unicode-char">&#8727;</span></span></a>
                    <div class="ce_e-address" id="eaddr0010" name="OPT_ID_784">philipp.bosshard@usz.ch</div>
                </div>
                <div class="ce_affiliation" id="aff1" name="OPT_ID_785"><span class="ce_textfn" name="OPT_ID_786">Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, CH-8091 Z<span class="unicode-char">&#252;</span>rich, Switzerland</span>
                    <div class="sa_affiliation" name="OPT_ID_787"><span class="sa_organization" id="authorgp" name="OPT_ID_788">Department of Dermatology</span><span class="x">, </span><span class="sa_organization" id="authorgp" name="OPT_ID_789">University Hospital Zurich</span><span class="x">, </span><span class="sa_address-line" id="authorgp" name="OPT_ID_790">Gloriastrasse 31</span><span class="x">, </span><span class="sa_city" id="authorgp" name="OPT_ID_791">Z<span class="unicode-char">&#252;</span>rich</span><span class="x">, </span><span class="sa_postal-code" id="authorgp" name="OPT_ID_792">CH-8091</span><span class="x">, </span><span class="sa_country" id="authorgp" name="OPT_ID_793">Switzerland</span></div>
                </div>
                <div class="ce_correspondence" id="cor1" name="OPT_ID_794"><span class="ce_label" name="OPT_ID_795"><span class="unicode-char">&#8727;</span></span><span class="ce_text" name="OPT_ID_796">Tel.:<span class="unicode-char">&#160;</span>+41 44 255 3972; fax:<span class="unicode-char">&#160;</span>+41 44 255 4418.</span>
                </div>
            </div>
            <span class="ce_date-accepted" name="OPT_ID_797"></span>
            <div class="ce_abstract" id="abs0010" name="OPT_ID_798"><span class="ce_section-title" name="OPT_ID_799">Summary</span>
                <div class="ce_abstract-sec" id="abssec0010" name="OPT_ID_800"><span class="ce_section-title" name="OPT_ID_801">Objectives<span class="x">&#160;</span></span><span class="newline_simplepara" name="OPT_ID_802">IgM antibodies are usually the first to be <span data-format-cpedel="true">produced</span><span data-format-cpeins="true">producing</span> during treponemal infection. Three commercially available enzyme immunoassays (EIA) for detection of IgM antibodies against <span class="ce_italic" name="OPT_ID_803">Treponema pallidum</span> were evaluated.</span>
                </div>
                <div class="ce_abstract-sec" id="abssec0015" name="OPT_ID_804"><span class="ce_section-title" name="OPT_ID_805">Methods<span class="x">&#160;</span></span><span class="newline_simplepara" name="OPT_ID_806">Results of the Anti-Treponema-pallidum-ELISA (IgM; Euroimmun), Pathozyme Syphilis M Capture (Omega Diagnostics) and recomWell Treponema IgM (Mikrogen) were compared with those of the <span class="ce_italic" name="OPT_ID_807">T. pallidum</span> particle agglutination (TPPA) and the Venereal Disease Research Laboratory (VDRL) tests for 307 serum samples.</span>
                </div>
                <div class="ce_abstract-sec" id="abssec0020" name="OPT_ID_808"><span class="ce_section-title" name="OPT_ID_809">Results<span class="x">&#160;</span></span><span class="newline_simplepara" name="OPT_ID_810">The overall sensitivity (95% confidence interval [CI]) of the TPPA was 100% (97.7<span class="unicode-char">&#8211;</span>100%) compared to 83.3% (76.5<span class="unicode-char">&#8211;</span>88.8%) of the VDRL, 88.5% (82.4<span class="unicode-char">&#8211;</span>93.0%) of the Pathozyme, 84.6% (78.0<span class="unicode-char">&#8211;</span>89.9) of the Euroimmun, and 73.6% (66.1<span class="unicode-char">&#8211;</span>80.4%) of a modified recomWell test procedure. Specificities were in the range of 91.4<span class="unicode-char">&#8211;</span>100%. In primary syphilis, sensitivities of the Pathozyme (89.8%; 95% CI, 79.2<span class="unicode-char">&#8211;</span>96.2%) and Euroimmun tests (81.4%; 95% CI, 69.1<span class="unicode-char">&#8211;</span>90.3%) were significantly higher (<span class="ce_italic" name="OPT_ID_811">p</span><span class="unicode-char">&#160;</span>&lt;<span class="unicode-char">&#160;</span>0.05) than the sensitivity of the VDRL test (61%; 95% CI, 47.4<span class="unicode-char">&#8211;</span>73.5%). IgM EIAs even were positive in some cases of suspected very early infection where the VDRL was non-reactive and the TPPA was indeterminate.</span>
                </div>
                <div class="ce_abstract-sec" id="abssec0025" name="OPT_ID_812"><span class="ce_section-title" name="OPT_ID_813">Conclusions<span class="x">&#160;</span></span><span class="newline_simplepara" name="OPT_ID_814">In cases of suspected early infection specific IgM EIAs should be used in addition to other screening tests. The VDRL is not recommended for screening.</span></div>
            </div>
            <div class="ce_keywords" name="OPT_ID_815"><span class="ce_section-title" name="OPT_ID_816">Keywords<span class="x">: </span></span><span class="ce_keyword" name="OPT_ID_817"><span class="ce_text" name="OPT_ID_818">Syphilis</span><span class="x">; </span></span><span class="ce_keyword" name="OPT_ID_819"><span class="ce_text" name="OPT_ID_820">Serology</span><span class="x">; </span></span><span class="ce_keyword" name="OPT_ID_821"><span class="ce_text" name="OPT_ID_822">IgM</span><span class="x">; </span></span><span class="ce_keyword" name="OPT_ID_823"><span class="ce_text" name="OPT_ID_824">ELISA</span><span class="x">; </span></span><span class="ce_keyword" name="OPT_ID_825"><span class="ce_text" name="OPT_ID_826">EIA</span><span class="x">; </span></span><span class="ce_keyword" name="OPT_ID_827"><span class="ce_text" name="OPT_ID_828">Diagnosis</span><span class="x">; </span></span><span class="ce_keyword" name="OPT_ID_829"><span class="ce_text" name="OPT_ID_830"><span class="ce_italic" name="OPT_ID_831">Treponema pallidum</span></span>
                </span>
            </div>
        </div>
        <div class="body" name="OPT_ID_832">
            <div class="ce_sections" name="OPT_ID_833">
                <div class="ce_section" id="sec1" name="OPT_ID_834">
                    <div class="sectionline_opt"><span class="ce_section-title" name="OPT_ID_835">Introduction</span></div>
                    <div class="ce_para" id="p0010" name="OPT_ID_836">Serology remains the mainstay of laboratory detection of <span class="ce_italic" name="OPT_ID_837">Treponema pallidum</span> infections. Two classes of antibody tests are available: treponemal and non-treponemal. In Europe, it is recommended to use a treponemal antigen test as a single screening test, e.g. an enzyme immunoassay (EIA) or the <span class="ce_italic" name="OPT_ID_838">T. pallidum</span> particle agglutination test<span class="unicode-char">&#160;</span>(TPPA),<a title="bib1" style="color:blue" class="ce_cross-ref" name="OPT_ID_839"><span class="ce_sup" name="OPT_ID_840">1</span></a> with positive samples being confirmed by a second<span class="unicode-char">&#160;</span>treponemal test. Non-treponemal tests, e.g. VDRL (Venereal Disease Research Laboratory) or RPR (Rapid Plasma Reagin), are useful for detection of active infection and for monitoring treatment response,<a title="bib2" style="color:blue" class="ce_cross-ref" name="OPT_ID_841"><span class="ce_sup" name="OPT_ID_842">2</span></a> however, they are less specific than treponemal tests and lack sensitivity in primary and late syphilis patients.<a title="bib2" style="color:blue" class="ce_cross-refs" name="OPT_ID_843"><span class="ce_sup" name="OPT_ID_844">2<span class="unicode-char">&#8211;</span>5</span></a> Additionally, they are labour intensive and cannot be run on automated platforms.</div>
                    <div class="ce_para" id="p0015" name="OPT_ID_845">IgM class antibodies are usually the first to be produced during treponemal infection.<a title="bib6" style="color:blue" class="ce_cross-ref" name="OPT_ID_846"><span class="ce_sup" name="OPT_ID_847">6</span></a> It has been shown that IgM-specific EIAs are very sensitive in detecting primary and secondary syphilis<a title="bib2" style="color:blue" class="ce_cross-refs" name="OPT_ID_848"><span class="ce_sup" name="OPT_ID_849">2,4,5,7<span class="unicode-char">&#8211;</span>10</span></a> with the IgM EIA being the first test positive in some instances. It is recommended to request a specific anti-treponemal IgM test if primary syphilis is suspected.<a title="bib1" style="color:blue" class="ce_cross-refs" name="OPT_ID_850"><span class="ce_sup" name="OPT_ID_851">1,2</span></a> Although many different commercial IgM EIA tests are available, few have been analysed for their performance at different stages of syphilis, namely the Mercia Syphilis M EIA (Microgen Products Ltd)<a title="bib4" style="color:blue" class="ce_cross-refs" name="OPT_ID_852"><span class="ce_sup" name="OPT_ID_853">4,5,8<span class="unicode-char">&#8211;</span>12</span></a> the Eti-syphilis-M (DiaSorin)<a title="bib7" style="color:blue" class="ce_cross-ref" name="OPT_ID_854"><span class="ce_sup" name="OPT_ID_855">7</span></a> and the recomWell Treponema IgM (Mikrogen).<a title="bib13" style="color:blue" class="ce_cross-ref" name="OPT_ID_856"><span class="ce_sup" name="OPT_ID_857">13</span></a> Additionally, the Mercia Syphilis M EIA has been evaluated for diagnosing maternal and congenital syphilis<a title="bib14" style="color:blue" class="ce_cross-ref" name="OPT_ID_858"><span class="ce_sup" name="OPT_ID_859">14</span></a> and the use of Euroimmun EIA and Western-blot IgG and IgM assays for screening blood donors has been investigated.<a title="bib15" style="color:blue" class="ce_cross-ref" name="OPT_ID_860"><span class="ce_sup" name="OPT_ID_861">15</span></a></div>
                    <div class="ce_para" id="p0020" name="OPT_ID_862">In the present study, three commercially available EIAs to detect IgM antibodies to <span class="ce_italic" name="OPT_ID_863">T. pallidum</span> were evaluated (Anti-Treponema-pallidum-ELISA IgM, Euroimmun; Pathozyme Syphilis M Capture, Omega Diagnostics; recomWell Treponema IgM, Mikrogen). Sensitivities were determined with consecutive sera from untreated syphilis patients at different disease stages. Specificities were analysed by a panel of sera including sera of patients with diseases potentially interfering with syphilis serology tests.</div>
                </div>
                <div class="ce_section" id="sec2" name="OPT_ID_864">
                    <div class="sectionline_opt"><span class="ce_section-title" name="OPT_ID_865">Materials and methods</span></div>
                    <div class="ce_section" id="sec2.1" name="OPT_ID_866">
                        <div class="sectionline_opt"><span class="ce_section-title" name="OPT_ID_867">Study design</span></div>
                        <div class="ce_para" id="p0025" name="OPT_ID_868">One hundred and fifty-six consecutive sera submitted to the syphilis serology laboratory at the Clinic of Dermatology, University Hospital of Zurich of patients at the Zurich University Hospital which were diagnosed between January 2008 and December 2010 having untreated syphilis were included in this retrospective study.</div>
                        <div class="ce_para" id="p0030" name="OPT_ID_869">Routine testing include the VDRL test (Dade Behring, D<span class="unicode-char">&#252;</span>dingen, Germany), the TPPA test (Fujirebio Inc., Tokyo, Japan), the Fluorescent Treponemal Antibody<span class="unicode-char">&#8211;</span>Absorption test (FTA-ABS, Biom<span class="unicode-char">&#233;</span>rieux, Gen<span class="unicode-char">&#232;</span>ve, Switzerland), and the Pathozyme Syphilis M Capture EIA (Omega Diagnostic Ltd., Alva, United Kingdom). After routine testing, sera were stored at <span class="unicode-char1">&#8722;</span>20<span class="ce_hsp" sp="0.25" name="OPT_ID_870">&#160;</span><span class="unicode-char">&#176;</span>C until further testing in 2011 with the Anti-Treponema-pallidum-ELISA (IgM; Euroimmun, L<span class="unicode-char">&#252;</span>beck, Germany) and the recomWell Treponema IgM (Mikrogen, Neuried, Germany).</div>
                        <div class="ce_para" id="p0035" name="OPT_ID_871">To assess the specificity, 151 sera were tested including sera known to be potentially cross-reactive (anti-<span class="ce_italic" name="OPT_ID_872">Borrelia burgdorferi</span> IgM [<span class="ce_italic" name="OPT_ID_873">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>10], anti-Epstein<span class="unicode-char">&#8211;</span>Barr virus IgM [<span class="ce_italic" name="OPT_ID_874">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>10], anti-Cytomegalovirus IgM [<span class="ce_italic" name="OPT_ID_875">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>10], auto-immune disease (Lupus erythematosus) [<span class="ce_italic" name="OPT_ID_876">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>1], HIV patients [<span class="ce_italic" name="OPT_ID_877">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>20] and pregnant women [<span class="ce_italic" name="OPT_ID_878">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>20]), negative sera without further specification (<span class="ce_italic" name="OPT_ID_879">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>50) and sera of previously treated syphilis patients (<span class="ce_italic" name="OPT_ID_880">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>30).</div>
                    </div>
                    <div class="ce_section" id="sec2.2" name="OPT_ID_881">
                        <div class="sectionline_opt"><span class="ce_section-title" name="OPT_ID_882">Patient characteristics</span></div>
                        <div class="ce_para" id="p0040" name="OPT_ID_883">Based on clinical data obtained from patients<span class="unicode-char">&#8217;</span> charts and serological results, patients were categorized as having primary syphilis (<span class="ce_italic" name="OPT_ID_884">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>59), secondary syphilis (<span class="ce_italic" name="OPT_ID_885">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>66), latent syphilis (<span class="ce_italic" name="OPT_ID_886">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>25), or tertiary syphilis (<span class="ce_italic" name="OPT_ID_887">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>6) (<a title="tbl1" style="color:blue" class="ce_cross-ref" name="OPT_ID_888">Table<span class="unicode-char">&#160;</span>1</a><span class="ce_float-anchor" refid="tbl1" name="OPT_ID_889"></span>). Fifty out of 59 primary syphilis patients had typical ulcers at ano-genital or oro-pharyngeal sites. The other nine patients had positive serology and erythematous lesions on the penis or the tonsils (<span class="ce_italic" name="OPT_ID_890">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>3) or a possible exposition to syphilis without clinic (<span class="ce_italic" name="OPT_ID_891">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>6). Secondary syphilis patients had muco-cutaneous skin lesions typical for secondary syphilis. Patients with latent syphilis had positive serology but without clinical signs of syphilis. Patients were classified as having tertiary syphilis based on a combination of clinical and serological findings as well as CSF analysis.</div>
                        <div class="table" id="tbl1" name="OPT_ID_9">
                            <div class="tablecaption"><span class="ce_label" name="OPT_ID_10">Table<span class="unicode-char">&#160;</span>1</span><span class="x">&#160;</span><span class="ce_caption" id="cap0010" name="OPT_ID_11"><span class="ce_simple-para" id="tspara0010" name="OPT_ID_12">Study population and assignment to disease stage.</span></span>
                            </div>
                            <table border="0" frame="hsides" class="topbot" name="OPT_ID_13">
                                <col width="19%"></col>
                                <col width="8%"></col>
                                <col width="23%"></col>
                                <col width="30%"></col>
                                <col width="15%"></col>
                                <thead title="thead" name="OPT_ID_19">
                                    <tr title="table-row" name="OPT_ID_20">
                                        <td class="td" title="table-head" align="" valign="top" name="OPT_ID_21">Syphilis stage</td>
                                        <td class="td" title="table-head" align="" valign="top" name="OPT_ID_22">No.</td>
                                        <td class="td" title="table-head" align="" valign="top" name="OPT_ID_23">Clinical characteristics</td>
                                        <td class="td" title="table-head" align="" valign="top" name="OPT_ID_24">Syphilis serology considered for assignment</td>
                                        <td class="td" title="table-head" align="" valign="top" name="OPT_ID_25">Remarks</td>
                                    </tr>
                                </thead>
                                <tbody title="tbody" name="OPT_ID_26">
                                    <tr title="table-row" name="OPT_ID_27">
                                        <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_28">Primary syphilis (<span class="ce_italic" name="OPT_ID_29">n</span><span class="ce_hsp" sp="0.2" name="OPT_ID_30">&#160;</span>=<span class="ce_hsp" sp="0.2" name="OPT_ID_31">&#160;</span>59)</td>
                                        <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_32" char=".">50</td>
                                        <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_33">Typical ulcers at ano-genital or oro-pharyngeal sites</td>
                                        <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_34">No</td>
                                        <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_35"><span class="unicode-char">&#8211;</span></td>
                                    </tr>
                                    <tr title="table-row" name="OPT_ID_36">
                                        <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_37"></td>
                                        <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_38" char=".">9</td>
                                        <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_39">Erythematous lesions on the penis or the tonsils (<span class="ce_italic" name="OPT_ID_40">n</span><span class="ce_hsp" sp="0.2" name="OPT_ID_41">&#160;</span>=<span class="ce_hsp" sp="0.2" name="OPT_ID_42">&#160;</span>3) or a possible exposition to syphilis without clinic (<span class="ce_italic" name="OPT_ID_43">n</span><span class="ce_hsp" sp="0.2" name="OPT_ID_44">&#160;</span>=<span class="ce_hsp" sp="0.2" name="OPT_ID_45">&#160;</span>6)</td>
                                        <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_46">IgM EIA positive (<span class="ce_italic" name="OPT_ID_47">n</span><span class="ce_hsp" sp="0.2" name="OPT_ID_48">&#160;</span>=<span class="ce_hsp" sp="0.2" name="OPT_ID_49">&#160;</span>9), TPPA positive (<span class="ce_italic" name="OPT_ID_50">n</span><span class="ce_hsp" sp="0.2" name="OPT_ID_51">&#160;</span>=<span class="ce_hsp" sp="0.2" name="OPT_ID_52">&#160;</span>4) or indeterminate (<span class="ce_italic" name="OPT_ID_53">n</span><span class="ce_hsp" sp="0.2" name="OPT_ID_54">&#160;</span>=<span class="ce_hsp" sp="0.2" name="OPT_ID_55">&#160;</span>5), VDRL positive (<span class="ce_italic" name="OPT_ID_56">n</span><span class="ce_hsp" sp="0.2" name="OPT_ID_57">&#160;</span>=<span class="ce_hsp" sp="0.2" name="OPT_ID_58">&#160;</span>3)</td>
                                        <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_59">IgM EIA decreased after therapy</td>
                                    </tr>
                                    <tr title="table-row" name="OPT_ID_60">
                                        <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_61">Secondary syphilis (<span class="ce_italic" name="OPT_ID_62">n</span><span class="ce_hsp" sp="0.2" name="OPT_ID_63">&#160;</span>=<span class="ce_hsp" sp="0.2" name="OPT_ID_64">&#160;</span>66)</td>
                                        <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_65" char=".">66</td>
                                        <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_66">Muco-cutaneous skin lesions typical for secondary syphilis</td>
                                        <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_67">No</td>
                                        <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_68">Four patients had concomitant genital or oral ulcers</td>
                                    </tr>
                                    <tr title="table-row" name="OPT_ID_69">
                                        <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_70">Latent syphilis (<span class="ce_italic" name="OPT_ID_71">n</span><span class="ce_hsp" sp="0.2" name="OPT_ID_72">&#160;</span>=<span class="ce_hsp" sp="0.2" name="OPT_ID_73">&#160;</span>25)</td>
                                        <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_74" char=".">25</td>
                                        <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_75">No clinical signs of syphilis</td>
                                        <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_76">Positive VDRL (<span class="ce_italic" name="OPT_ID_77">n</span><span class="ce_hsp" sp="0.2" name="OPT_ID_78">&#160;</span>=<span class="ce_hsp" sp="0.2" name="OPT_ID_79">&#160;</span>24), positive TPPA (<span class="ce_italic" name="OPT_ID_80">n</span><span class="ce_hsp" sp="0.2" name="OPT_ID_81">&#160;</span>=<span class="ce_hsp" sp="0.2" name="OPT_ID_82">&#160;</span>25), positive IgM EIA (<span class="ce_italic" name="OPT_ID_83">n</span><span class="ce_hsp" sp="0.2" name="OPT_ID_84">&#160;</span>=<span class="ce_hsp" sp="0.2" name="OPT_ID_85">&#160;</span>23); suggesting latent syphilis (see also <a title="tbl2" style="color:blue" class="ce_cross-ref" name="OPT_ID_86">Table<span class="unicode-char">&#160;</span>2</a>)</td>
                                        <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_87"><span class="unicode-char">&#8211;</span></td>
                                    </tr>
                                    <tr title="table-row" name="OPT_ID_88">
                                        <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_89">Tertiary syphilis (<span class="ce_italic" name="OPT_ID_90">n</span><span class="ce_hsp" sp="0.2" name="OPT_ID_91">&#160;</span>=<span class="ce_hsp" sp="0.2" name="OPT_ID_92">&#160;</span>6)</td>
                                        <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_93" char=".">6</td>
                                        <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_94">Neurosyphilis (<span class="ce_italic" name="OPT_ID_95">n</span><span class="ce_hsp" sp="0.2" name="OPT_ID_96">&#160;</span>=<span class="ce_hsp" sp="0.2" name="OPT_ID_97">&#160;</span>5), luetic aneurysm (<span class="ce_italic" name="OPT_ID_98">n</span><span class="ce_hsp" sp="0.2" name="OPT_ID_99">&#160;</span>=<span class="ce_hsp" sp="0.2" name="OPT_ID_100">&#160;</span>1)</td>
                                        <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_101">For the neurosyphilis patients: positive CSF<span class="unicode-char">&#8211;</span>VDRL (<span class="ce_italic" name="OPT_ID_102">n</span><span class="ce_hsp" sp="0.2" name="OPT_ID_103">&#160;</span>=<span class="ce_hsp" sp="0.2" name="OPT_ID_104">&#160;</span>4), CSF pleocytosis and elevated protein (<span class="ce_italic" name="OPT_ID_105">n</span><span class="ce_hsp" sp="0.2" name="OPT_ID_106">&#160;</span>=<span class="ce_hsp" sp="0.2" name="OPT_ID_107">&#160;</span>1)</td>
                                        <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_108"><span class="unicode-char">&#8211;</span></td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                    <div class="ce_section" id="sec2.3" name="OPT_ID_892">
                        <div class="sectionline_opt"><span class="ce_section-title" name="OPT_ID_893">Serological testing</span></div>
                        <div class="ce_para" id="p0045" name="OPT_ID_894">All tests were performed according to the manufacturer<span class="unicode-char">&#8217;</span>s instructions. To avoid false-negative results due to the prozone phenomenon the VDRL was tested up to a 1:64 dilution.</div>
                        <div class="ce_para" id="p0050" name="OPT_ID_895">The three EIAs are designed for the semi-quantitative detection of IgM antibodies against <span class="ce_italic" name="OPT_ID_896">T. pallidum</span>. The Euroimmun Anti-Treponema-pallidum-ELISA (IgM) and the recomWell Treponema IgM both involve indirect <span class="unicode-char">&#8216;</span>sandwich<span class="unicode-char">&#8217;</span> EIA procedures using microtitration wells coated with the recombinant treponemal antigens Tp15, Tp17, Tp47 and TmpA. After incubation with the test serum, bound IgM antibodies are detected with an enzyme-labelled anti-human-IgM antibody. For the Euroimmun Anti-Treponema-pallidum-ELISA (IgM), prior to incubation with the test serum, interfering IgG antibodies are precipitated with anti-human-IgG antibodies. Results are calculated as index values (optical density of sample/cut-off value) and are then classified as negative (&lt;0.8), equivocal (<span class="unicode-char">&#8805;</span>0.8, &lt;1.1) or positive (<span class="unicode-char">&#8805;</span>1.1).</div>
                        <div class="ce_para" id="p0055" name="OPT_ID_897">According to the manufacturer<span class="unicode-char">&#8217;</span>s protocol for the recomWell a pre-adsorption of IgG antibodies must not be done. However, due to moderate performance all samples were also tested with a modified recomWell Treponema IgM protocol in which interfering IgG antibodies were precipitated with Gullsorb reagent (Meridian Bioscience, Ohio, United States) containing anti-human-IgG antibodies according to the manufacturer<span class="unicode-char">&#8217;</span>s protocol. For the recomWell Treponema IgM, results are calculated as antibody units per ml (optical density of sample/cut-off value<span class="ce_hsp" sp="0.2" name="OPT_ID_898">&#160;</span><span class="unicode-char">&#215;</span><span class="ce_hsp" sp="0.2" name="OPT_ID_899">&#160;</span>20) and are then classified as negative (&lt;20), equivocal (<span class="unicode-char">&#8805;</span>20, <span class="unicode-char">&#8804;</span>24) or positive (&gt;24).</div>
                        <div class="ce_para" id="p0060" name="OPT_ID_900">In the Pathozyme Syphilis M Capture EIA microtitration wells are coated with anti-human-IgM which captures IgM antibodies in the test serum onto the well. After washing a conjugate of native <span class="ce_italic" name="OPT_ID_901">T. pallidum</span> antigen (Tp15, Tp17, Tp44 and Tp47) labelled with horseradish peroxidase is applied. Results are calculated as index values (optical density of sample/cut-off value) and are then classified as negative (&lt;0.9), equivocal (<span class="unicode-char">&#8805;</span>0.9, <span class="unicode-char">&#8804;</span>1.1) or positive (&gt;1.1).</div>
                        <div class="ce_para" id="p0065" name="OPT_ID_902">Equivocal results of any of the specific IgM EIAs were repeated and the second result was accepted as the final one. Thus, 27 positive sera and 5 control sera had to be repeated, i.e., 14 Euroimmun, 6 recomWell, and 12 Pathozyme tests. In 10, 12, and 10 cases, respectively, results became negative, became positive, or remained equivocal upon repetition. Repeated equivocal results were considered as positive for calculating sensitivity and specificity.</div>
                    </div>
                    <div class="ce_section" id="sec2.4" name="OPT_ID_903">
                        <div class="sectionline_opt"><span class="ce_section-title" name="OPT_ID_904">Statistical analysis</span></div>
                        <div class="ce_para" id="p0070" name="OPT_ID_905">Confidence intervals were calculated with GraphPad Prism, Version 5.04 (GraphPad Software, Inc., La Jolla, California). Sensitivities were compared with the McNemar <span class="ce_italic" name="OPT_ID_906"><span class="unicode-char">&#967;</span></span><span class="ce_sup" name="OPT_ID_907">2</span> test<a title="bib16" style="color:blue" class="ce_cross-ref" name="OPT_ID_908"><span class="ce_sup" name="OPT_ID_909">16</span></a> online at <a name="OPT_ID_910" class="ce_inter-ref">http://graphpad.com/QuickCalcs</a> (GraphPad Software, Inc., La Jolla, California last accessed 9th January 2013).</div>
                    </div>
                </div>
                <div class="ce_section" id="sec3" name="OPT_ID_911">
                    <div class="sectionline_opt"><span class="ce_section-title" name="OPT_ID_912">Results</span></div>
                    <div class="ce_para" id="p0075" name="OPT_ID_913">Results of all tests are shown in <a title="tbl2" style="color:blue" class="ce_cross-ref" name="OPT_ID_914">Tables<span class="unicode-char">&#160;</span>2</a> and <a title="tbl3" style="color:blue" class="ce_cross-ref" name="OPT_ID_915">3</a><span class="ce_float-anchor" refid="tbl2" name="OPT_ID_916"></span><span class="ce_float-anchor" refid="tbl3" name="OPT_ID_917"></span> and corresponding sensitivities and specificities are depicted in <a title="tbl4" style="color:blue" class="ce_cross-ref" name="OPT_ID_918">Table<span class="unicode-char">&#160;</span>4</a><span class="ce_float-anchor" refid="tbl4" name="OPT_ID_919"></span>. In 148/156 patients the TPPA test was positive and in 8/156 it was equivocal/indeterminate. The VDRL test was positive or equivocal in 36/59 (61%) patients with primary syphilis, positive in 64/66 (97%) patients with secondary syphilis, in 24/25 (96%) patients with latent syphilis and in all six patients with tertiary syphilis. VDRL and TPPA titres were lower in primary syphilis compared to secondary, latent or tertiary syphilis (<a title="tbl2" style="color:blue" class="ce_cross-ref" name="OPT_ID_920">Table<span class="unicode-char">&#160;</span>2</a>).</div>
                    <div class="table" id="tbl2" name="OPT_ID_109">
                        <div class="tablecaption"><span class="ce_label" name="OPT_ID_110">Table<span class="unicode-char">&#160;</span>2</span><span class="x">&#160;</span><span class="ce_caption" id="cap0015" name="OPT_ID_111"><span class="ce_simple-para" id="tspara0015" name="OPT_ID_112">Results of TPPA, VDRL and IgM-specific EIAs according to syphilis disease stage.</span></span>
                        </div>
                        <table border="0" frame="hsides" class="topbot" name="OPT_ID_113">
                            <col width="19%"></col>
                            <col width="15%"></col>
                            <col width="17%"></col>
                            <col width="17%"></col>
                            <col width="17%"></col>
                            <col width="11%"></col>
                            <thead title="thead" name="OPT_ID_120">
                                <tr title="table-row" name="OPT_ID_121">
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_122">Assay</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_123">Primary syphilis (<span class="ce_italic" name="OPT_ID_124">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>59)</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_125">Secondary syphilis (<span class="ce_italic" name="OPT_ID_126">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>66)</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_127">Latent syphilis (<span class="ce_italic" name="OPT_ID_128">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>25)</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_129">Tertiary syphilis (<span class="ce_italic" name="OPT_ID_130">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>6)</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_131">Total (<span class="ce_italic" name="OPT_ID_132">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>156)</td>
                                </tr>
                            </thead>
                            <tbody title="tbody" name="OPT_ID_133">
                                <tr title="table-row" name="OPT_ID_134">
                                    <td class="td" title="table-entry" colspan="6" align="" valign="top" name="OPT_ID_135">TPPA</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_136">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_137"><span class="ce_hsp" sp="1" name="OPT_ID_138">&#160;</span>Median titres</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_139">1:320</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_140">1:20480</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_141">1:40960</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_142">1:61440</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_143">1:10240</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_144">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_145"><span class="ce_hsp" sp="1" name="OPT_ID_146">&#160;</span>Interquartile range</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_147">1:160, 1:5120</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_148">1:5120, 1:81920</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_149">1:10240, 1:163840</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_150">1:25600, 1:143360</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_151">1:640, 1:40960</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_152">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_153"><span class="ce_hsp" sp="1" name="OPT_ID_154">&#160;</span>Negative, no. (%)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_155">0</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_156">0</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_157">0</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_158">0</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_159">0</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_160">
                                    <td class="td" title="table-entry" colspan="6" align="" valign="top" name="OPT_ID_161"><span class="ce_vsp" name="OPT_ID_162" vspace="0.5"></span></td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_163">
                                    <td class="td" title="table-entry" colspan="6" align="" valign="top" name="OPT_ID_164">VDRL</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_165">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_166"><span class="ce_hsp" sp="1" name="OPT_ID_167">&#160;</span>Median titer</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_168">1:2</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_169">1:32</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_170">1:32</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_171">1: 40</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_172">1:16</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_173">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_174"><span class="ce_hsp" sp="1" name="OPT_ID_175">&#160;</span>Interquartile range</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_176">1:0, 1:16</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_177">1:16, 1:64</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_178">1:8, 1:64</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_179">1:16, 1:112</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_180">1:4, 1:64</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_181">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_182"><span class="ce_hsp" sp="1" name="OPT_ID_183">&#160;</span>Negative, no. (%)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_184">23 (39)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_185">2 (3)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_186">1 (4)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_187">0</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_188">26 (16.7)</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_189">
                                    <td class="td" title="table-entry" colspan="6" align="" valign="top" name="OPT_ID_190"><span class="ce_vsp" name="OPT_ID_191" vspace="0.5"></span></td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_192">
                                    <td class="td" title="table-entry" colspan="6" align="" valign="top" name="OPT_ID_193">Pathozyme-IgM</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_194">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_195"><span class="ce_hsp" sp="1" name="OPT_ID_196">&#160;</span>Median titer</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_197">2.24</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_198">3.14</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_199">1.67</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_200">1.71</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_201">2.51</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_202">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_203"><span class="ce_hsp" sp="1" name="OPT_ID_204">&#160;</span>Interquartile range</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_205">1.42<span class="unicode-char">&#8211;</span>3.03</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_206">2.0 to &gt;3.5</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_207">1.19<span class="unicode-char">&#8211;</span>2.62</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_208">&lt;0.90<span class="unicode-char">&#8211;</span>2.78</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_209">1.491<span class="unicode-char">&#8211;</span>3.50</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_210">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_211"><span class="ce_hsp" sp="1" name="OPT_ID_212">&#160;</span>Negative, no. (%)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_213">6 (10.2)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_214">6 (9.1)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_215">4 (16)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_216">2 (33.3)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_217">18 (11.5)</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_218">
                                    <td class="td" title="table-entry" colspan="6" align="" valign="top" name="OPT_ID_219"><span class="ce_vsp" name="OPT_ID_220" vspace="0.5"></span></td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_221">
                                    <td class="td" title="table-entry" colspan="6" align="" valign="top" name="OPT_ID_222">Euroimmun</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_223">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_224"><span class="ce_hsp" sp="1" name="OPT_ID_225">&#160;</span>Median titer</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_226">2.11</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_227">4.67</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_228">1.24</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_229">5.55</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_230">3.01</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_231">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_232"><span class="ce_hsp" sp="1" name="OPT_ID_233">&#160;</span>Interquartile range</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_234">1.12<span class="unicode-char">&#8211;</span>3.52</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_235">1.91<span class="unicode-char">&#8211;</span>7.07</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_236">&lt;0.8<span class="unicode-char">&#8211;</span>4.65</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_237">3.86<span class="unicode-char">&#8211;</span>7.0</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_238">1.24<span class="unicode-char">&#8211;</span>5.86</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_239">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_240"><span class="ce_hsp" sp="1" name="OPT_ID_241">&#160;</span>Negative, no. (%)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_242">11 (18.6)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_243">5 (7.6)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_244">8 (32)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_245">0</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_246">24 (15.4)</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_247">
                                    <td class="td" title="table-entry" colspan="6" align="" valign="top" name="OPT_ID_248"><span class="ce_vsp" name="OPT_ID_249" vspace="0.5"></span></td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_250">
                                    <td class="td" title="table-entry" colspan="6" align="" valign="top" name="OPT_ID_251">recomWell</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_252">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_253"><span class="ce_hsp" sp="1" name="OPT_ID_254">&#160;</span>Median titer</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_255">20.4</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_256">59.7</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_257">19.2</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_258">63.3</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_259">35.7</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_260">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_261"><span class="ce_hsp" sp="1" name="OPT_ID_262">&#160;</span>Interquartile range</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_263">&lt;20.0<span class="unicode-char">&#8211;</span>50.0</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_264">27.6<span class="unicode-char">&#8211;</span>99.5</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_265">&lt;20.0<span class="unicode-char">&#8211;</span>66.7</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_266">36.3<span class="unicode-char">&#8211;</span>73.8</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_267">&lt;20.0<span class="unicode-char">&#8211;</span>75.2</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_268">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_269"><span class="ce_hsp" sp="1" name="OPT_ID_270">&#160;</span>Negative, no. (%)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_271">29 (49.2)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_272">13 (19.7)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_273">13 (52)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_274">1 (16.7)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_275">56 (35.9)</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_276">
                                    <td class="td" title="table-entry" colspan="6" align="" valign="top" name="OPT_ID_277"><span class="ce_vsp" name="OPT_ID_278" vspace="0.5"></span></td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_279">
                                    <td class="td" title="table-entry" colspan="6" align="" valign="top" name="OPT_ID_280">Modified recomWell</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_281">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_282"><span class="ce_hsp" sp="1" name="OPT_ID_283">&#160;</span>Median titer</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_284">26.1</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_285">83.9</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_286">25.3</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_287">97.0</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_288">42.1</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_289">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_290"><span class="ce_hsp" sp="1" name="OPT_ID_291">&#160;</span>Interquartile range</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_292">&lt;20.0<span class="unicode-char">&#8211;</span>46.7</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_293">36.1<span class="unicode-char">&#8211;</span>135.0</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_294">&lt;20.0<span class="unicode-char">&#8211;</span>88.7</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_295">46.4<span class="unicode-char">&#8211;</span>170.2</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_296">&lt;20.0<span class="unicode-char">&#8211;</span>97.7</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_297">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_298"><span class="ce_hsp" sp="1" name="OPT_ID_299">&#160;</span>Negative, no. (%)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_300">22 (37.3)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_301">8 (12.1)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_302">10 (40)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_303">1 (16.7)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_304">41 (26.3)</td>
                                </tr>
                            </tbody>
                        </table>
                        <div class="ce_legend" name="OPT_ID_305">
                            <div title="legend" id="tspara0020" name="OPT_ID_306">TPPA, <span class="ce_italic" name="OPT_ID_307">Treponema pallidum</span> particle agglutination; and VDRL, Venereal Disease Research Laboratory.</div>
                        </div>
                    </div>
                    <div class="table" id="tbl3" name="OPT_ID_308">
                        <div class="tablecaption"><span class="ce_label" name="OPT_ID_309">Table<span class="unicode-char">&#160;</span>3</span><span class="x">&#160;</span><span class="ce_caption" id="cap0020" name="OPT_ID_310"><span class="ce_simple-para" id="tspara0025" name="OPT_ID_311">Results (no. of samples positive, equivocal and negative) of TPPA, VDRL and IgM-specific EIAs of 151 negative control sera.</span></span>
                        </div>
                        <table border="0" frame="hsides" class="topbot" name="OPT_ID_312">
                            <col width="20%"></col>
                            <col width="3%"></col>
                            <col width="3%"></col>
                            <col width="4%"></col>
                            <col width="3%"></col>
                            <col width="3%"></col>
                            <col width="4%"></col>
                            <col width="4%"></col>
                            <col width="3%"></col>
                            <col width="4%"></col>
                            <col width="4%"></col>
                            <col width="3%"></col>
                            <col width="4%"></col>
                            <col width="4%"></col>
                            <col width="3%"></col>
                            <col width="4%"></col>
                            <col width="6%"></col>
                            <col width="5%"></col>
                            <col width="5%"></col>
                            <thead title="thead" name="OPT_ID_332">
                                <tr title="table-row" name="OPT_ID_333">
                                    <td class="td" title="table-head" rowspan="2" align="" valign="top" name="OPT_ID_334">Specimen category</td>
                                    <td class="td" title="table-head" colspan="3" align="" valign="top" name="OPT_ID_335">TPPA</td>
                                    <td class="td" title="table-head" colspan="3" align="" valign="top" name="OPT_ID_336">VDRL</td>
                                    <td class="td" title="table-head" colspan="3" align="" valign="top" name="OPT_ID_337">Pathozyme</td>
                                    <td class="td" title="table-head" colspan="3" align="" valign="top" name="OPT_ID_338">Euroimmun</td>
                                    <td class="td" title="table-head" colspan="3" align="" valign="top" name="OPT_ID_339">recomWell</td>
                                    <td class="td" title="table-head" colspan="3" align="" valign="top" name="OPT_ID_340">Modified recomWell</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_341">
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_342">Pos</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_343">Eq</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_344">Neg</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_345">Pos</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_346">Eq</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_347">Neg</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_348">Pos</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_349">Eq</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_350">Neg</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_351">Pos</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_352">Eq</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_353">Neg</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_354">Pos</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_355">Eq</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_356">Neg</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_357">Pos</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_358">Eq</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_359">Neg</td>
                                </tr>
                            </thead>
                            <tbody title="tbody" name="OPT_ID_360">
                                <tr title="table-row" name="OPT_ID_361">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_362">Borrelia (<span class="ce_italic" name="OPT_ID_363">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>10)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_364" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_365" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_366" char=".">10</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_367" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_368" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_369" char=".">10</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_370" char=".">1</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_371" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_372" char=".">9</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_373" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_374" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_375" char=".">10</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_376" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_377" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_378" char=".">10</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_379" char=".">1</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_380" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_381" char=".">9</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_382">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_383">EBV (<span class="ce_italic" name="OPT_ID_384">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>10)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_385" char=".">1</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_386" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_387" char=".">9</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_388" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_389" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_390" char=".">9<a title="tbl3fna" style="color:blue" class="ce_cross-ref" name="OPT_ID_391"><span class="ce_sup" name="OPT_ID_392">a</span></a></td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_393" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_394" char=".">1</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_395" char=".">9</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_396" char=".">7</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_397" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_398" char=".">3</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_399" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_400" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_401" char=".">10</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_402" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_403" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_404" char=".">10</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_405">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_406">CMV (<span class="ce_italic" name="OPT_ID_407">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>10)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_408" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_409" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_410" char=".">10</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_411" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_412" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_413" char=".">10</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_414" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_415" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_416" char=".">10</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_417" char=".">3</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_418" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_419" char=".">7</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_420" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_421" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_422" char=".">10</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_423" char=".">1</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_424" char=".">1</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_425" char=".">8</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_426">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_427">HIV (<span class="ce_italic" name="OPT_ID_428">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>20)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_429" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_430" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_431" char=".">20</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_432" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_433" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_434" char=".">20</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_435" char=".">2</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_436" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_437" char=".">18</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_438" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_439" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_440" char=".">20</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_441" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_442" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_443" char=".">20</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_444" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_445" char=".">1</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_446" char=".">19</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_447">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_448">Pregnant (<span class="ce_italic" name="OPT_ID_449">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>20)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_450" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_451" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_452" char=".">20</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_453" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_454" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_455" char=".">20</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_456" char=".">1</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_457" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_458" char=".">19</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_459" char=".">1</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_460" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_461" char=".">19</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_462" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_463" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_464" char=".">20</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_465" char=".">1</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_466" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_467" char=".">19</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_468">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_469">Lupus (<span class="ce_italic" name="OPT_ID_470">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>1)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_471" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_472" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_473" char=".">1</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_474" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_475" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_476" char=".">1</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_477" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_478" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_479" char=".">1</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_480" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_481" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_482" char=".">1</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_483" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_484" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_485" char=".">1</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_486" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_487" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_488" char=".">1</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_489">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_490">Treated syphilis (<span class="ce_italic" name="OPT_ID_491">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>30)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_492" char=".">25</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_493" char=".">5</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_494" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_495" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_496" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_497" char=".">30</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_498" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_499" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_500" char=".">30</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_501" char=".">1</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_502" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_503" char=".">29</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_504" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_505" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_506" char=".">30</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_507" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_508" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_509" char=".">30</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_510">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_511">Negative (<span class="ce_italic" name="OPT_ID_512">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>50)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_513" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_514" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_515" char=".">50</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_516" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_517" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_518" char=".">50</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_519" char=".">1</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_520" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_521" char=".">49</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_522" char=".">1</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_523" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_524" char=".">49</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_525" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_526" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_527" char=".">50</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_528" char=".">2</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_529" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_530" char=".">48</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_531">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_532">Total (<span class="ce_italic" name="OPT_ID_533">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>151)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_534" char=".">26</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_535" char=".">5</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_536" char=".">120</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_537" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_538" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_539" char=".">151</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_540" char=".">5</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_541" char=".">1</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_542" char=".">145</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_543" char=".">13</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_544" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_545" char=".">138</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_546" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_547" char=".">0</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_548" char=".">151</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_549" char=".">5</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_550" char=".">2</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_551" char=".">144</td>
                                </tr>
                            </tbody>
                        </table>
                        <div class="ce_legend" name="OPT_ID_552">
                            <div title="legend" id="tspara0030" name="OPT_ID_553">TPPA, <span class="ce_italic" name="OPT_ID_554">Treponema pallidum</span> particle agglutination; VDRL, Venereal Disease Research Laboratory; Pos, positive; Eq, equivocal; Neg, negative; <span class="ce_italic" name="OPT_ID_555">Borrelia</span>, anti-<span class="ce_italic" name="OPT_ID_556">Borrelia burgdorferi</span> IgM and IgG positive; EBV, anti-Epstein<span class="unicode-char">&#8211;</span>Barr virus IgM positive; CMV, anti-Cytomegalovirus IgM positive; HIV, HIV patients; Pregnant; pregnant women; Lupus, cutaneous Lupus erythematosus; Treated syphilis, previously treated syphilis patients; and Negative, negative sera without further specification.</div>
                        </div>
                        <div title="table-footnote" class="ce_table-footnote" id="tbl3fna" name="OPT_ID_557"><span class="ce_label" name="OPT_ID_558">a</span><span class="ce_note-para" id="ntpara0010" name="OPT_ID_559">VDRL could not be performed in one patient as too few serum was available.</span></div>
                    </div>
                    <div class="table" id="tbl4" name="OPT_ID_560">
                        <div class="tablecaption"><span class="ce_label" name="OPT_ID_561">Table<span class="unicode-char">&#160;</span>4</span><span class="x">&#160;</span><span class="ce_caption" id="cap0025" name="OPT_ID_562"><span class="ce_simple-para" id="tspara0035" name="OPT_ID_563">Sensitivities and specificities of TPPA, VDRL and IgM-specific EIAs<a title="tbl4fna" style="color:blue" class="ce_cross-ref" name="OPT_ID_564"><span class="ce_sup" name="OPT_ID_565">a</span></a>.</span>
                            </span>
                        </div>
                        <table border="0" frame="hsides" class="topbot" name="OPT_ID_566">
                            <col width="17%"></col>
                            <col width="15%"></col>
                            <col width="16%"></col>
                            <col width="16%"></col>
                            <col width="15%"></col>
                            <col width="16%"></col>
                            <thead title="thead" name="OPT_ID_573">
                                <tr title="table-row" name="OPT_ID_574">
                                    <td class="td" title="table-head" rowspan="2" align="" valign="top" name="OPT_ID_575">Test</td>
                                    <td class="td" title="table-head" colspan="4" align="" valign="top" name="OPT_ID_576">% Sensitivity (95% CI)</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_577">% Specificity (95% CI)</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_578">
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_579">Overall (<span class="ce_italic" name="OPT_ID_580">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>156)</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_581">Primary syphilis (<span class="ce_italic" name="OPT_ID_582">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>59)</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_583">Secondary syphilis (<span class="ce_italic" name="OPT_ID_584">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>66)</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_585">Latent syphilis (<span class="ce_italic" name="OPT_ID_586">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>25)</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_587"><span class="ce_italic" name="OPT_ID_588">n</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>151</td>
                                </tr>
                            </thead>
                            <tbody title="tbody" name="OPT_ID_589">
                                <tr title="table-row" name="OPT_ID_590">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_591">TPPA</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_592" char="(">100 (97.7<span class="unicode-char">&#8211;</span>100)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_593" char="(">100 (93.9<span class="unicode-char">&#8211;</span>100)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_594" char="(">100 (94.6<span class="unicode-char">&#8211;</span>100)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_595" char="(">100 (86.3<span class="unicode-char">&#8211;</span>100)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_596" char="(">99.2<a title="tbl4fnb" style="color:blue" class="ce_cross-ref" name="OPT_ID_597"><span class="ce_sup" name="OPT_ID_598">b</span></a> (95.5<span class="unicode-char">&#8211;</span>100)</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_599">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_600">VDRL</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_601" char="(">83.3 (76.5<span class="unicode-char">&#8211;</span>88.8)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_602" char="(">61.0 (47.4<span class="unicode-char">&#8211;</span>73.5)<a title="tbl4fnc" style="color:blue" class="ce_cross-ref" name="OPT_ID_603"><span class="ce_sup" name="OPT_ID_604">c</span></a></td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_605" char="(">97.0 (89.5<span class="unicode-char">&#8211;</span>99.6)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_606" char="(">96.0 (79.7<span class="unicode-char">&#8211;</span>99.9)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_607" char="(">100 (97.6<span class="unicode-char">&#8211;</span>100)</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_608">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_609">Pathozyme</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_610" char="(">88.5 (82.4<span class="unicode-char">&#8211;</span>93.0)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_611" char="(">89.8 (79.2<span class="unicode-char">&#8211;</span>96.2)<a title="tbl4fnc" style="color:blue" class="ce_cross-ref" name="OPT_ID_612"><span class="ce_sup" name="OPT_ID_613">c</span></a></td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_614" char="(">90.9 (81.3<span class="unicode-char">&#8211;</span>96.6)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_615" char="(">84.0 (63.9<span class="unicode-char">&#8211;</span>95.5)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_616" char="(">96.0 (91.6<span class="unicode-char">&#8211;</span>98.5)</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_617">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_618">Euroimmun</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_619" char="(">84.6 (78.0<span class="unicode-char">&#8211;</span>89.9)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_620" char="(">81.4 (69.1<span class="unicode-char">&#8211;</span>90.3)<a title="tbl4fnc" style="color:blue" class="ce_cross-ref" name="OPT_ID_621"><span class="ce_sup" name="OPT_ID_622">c</span></a></td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_623" char="(">92.4 (83.2<span class="unicode-char">&#8211;</span>97.5)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_624" char="(">68.0 (46.5<span class="unicode-char">&#8211;</span>85.1)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_625" char="(">91.4 (85.7<span class="unicode-char">&#8211;</span>95.3)</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_626">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_627">recomWell</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_628" char="(">64.1 (56.0<span class="unicode-char">&#8211;</span>71.6)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_629" char="(">50.8 (37.5<span class="unicode-char">&#8211;</span>65.1)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_630" char="(">80.3 (68.7<span class="unicode-char">&#8211;</span>89.1)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_631" char="(">48.0 (27.8<span class="unicode-char">&#8211;</span>68.7)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_632" char="(">100 (97.6<span class="unicode-char">&#8211;</span>100)</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_633">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_634">Modified recomWell</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_635" char="(">73.7 (66.1<span class="unicode-char">&#8211;</span>80.4)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_636" char="(">62.7 (49.2<span class="unicode-char">&#8211;</span>75.0)<a title="tbl4fnc" style="color:blue" class="ce_cross-ref" name="OPT_ID_637"><span class="ce_sup" name="OPT_ID_638">c</span></a></td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_639" char="(">87.9 (77.5<span class="unicode-char">&#8211;</span>94.6)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_640" char="(">60.0 (38.7<span class="unicode-char">&#8211;</span>78.9)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_641" char="(">95.4 (90.7<span class="unicode-char">&#8211;</span>98.1)</td>
                                </tr>
                            </tbody>
                        </table>
                        <div class="ce_legend" name="OPT_ID_642">
                            <div title="legend" id="tspara0040" name="OPT_ID_643">TPPA, <span class="ce_italic" name="OPT_ID_644">Treponema pallidum</span> particle agglutination; and VDRL, Venereal Disease Research Laboratory.</div>
                        </div>
                        <div title="table-footnote" class="ce_table-footnote" id="tbl4fna" name="OPT_ID_645"><span class="ce_label" name="OPT_ID_646">a</span><span class="ce_note-para" id="ntpara0015" name="OPT_ID_647">Equivocal results were considered as positive result for calculating sensitivity and specificity.</span></div>
                        <div title="table-footnote" class="ce_table-footnote" id="tbl4fnb" name="OPT_ID_648"><span class="ce_label" name="OPT_ID_649">b</span><span class="ce_note-para" id="ntpara0020" name="OPT_ID_650">For calculating the specificity of TPPA the 30 samples of previously treated syphilis patients were not considered.</span></div>
                        <div title="table-footnote" class="ce_table-footnote" id="tbl4fnc" name="OPT_ID_651"><span class="ce_label" name="OPT_ID_652">c</span><span class="ce_note-para" id="ntpara0025" name="OPT_ID_653">Results of McNemar<span class="unicode-char">&#8217;</span>s <span class="ce_italic" name="OPT_ID_654"><span class="unicode-char">&#967;</span></span><span class="ce_sup" name="OPT_ID_655">2</span> test; Pathozyme versus VDRL, <span class="ce_italic" name="OPT_ID_656"><span class="unicode-char">&#967;</span></span><span class="ce_sup" name="OPT_ID_657">2</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>9.5, <span class="ce_italic" name="OPT_ID_658">p</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>0.002; Pathozyme versus modified recomWell, <span class="ce_italic" name="OPT_ID_659"><span class="unicode-char">&#967;</span></span><span class="ce_sup" name="OPT_ID_660">2</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>11.3, <span class="ce_italic" name="OPT_ID_661">p</span><span class="unicode-char">&#160;</span>&lt;<span class="unicode-char">&#160;</span>0.001; Euroimmun versus VDRL, <span class="ce_italic" name="OPT_ID_662"><span class="unicode-char">&#967;</span></span><span class="ce_sup" name="OPT_ID_663">2</span>=<span class="unicode-char">&#160;</span>5.5, <span class="ce_italic" name="OPT_ID_664">p</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>0.019; and Euroimmun versus modified recomWell, <span class="ce_italic" name="OPT_ID_665"><span class="unicode-char">&#967;</span></span><span class="ce_sup" name="OPT_ID_666">2</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>9.1, <span class="ce_italic" name="OPT_ID_667">p</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>0.003.</span>
                        </div>
                    </div>
                    <div class="ce_para" id="p0080" name="OPT_ID_921">The IgM-specific EIAs started with low to moderate high scores in primary syphilis and had a peak in secondary and to a lesser extent in tertiary syphilis, while in latent syphilis the scores were lowest (<a title="tbl2" style="color:blue" class="ce_cross-ref" name="OPT_ID_922">Table<span class="unicode-char">&#160;</span>2</a>). A total of 138 (88.5%), 100 (64.1), and 132 (84.6%) of 156 sera of syphilis patients were tested positive by the IgM-specific Pathozyme, recomWell, and Euroimmun tests, respectively (<a title="tbl2" style="color:blue" class="ce_cross-ref" name="OPT_ID_923">Tables<span class="unicode-char">&#160;</span>2</a> and <a title="tbl4" style="color:blue" class="ce_cross-ref" name="OPT_ID_924">4</a>). As the recomWell Treponema IgM initially showed moderate performance all specimens were retested with a modified protocol what resulted in a significantly (McNemar <span class="ce_italic" name="OPT_ID_925"><span class="unicode-char">&#967;</span></span><span class="ce_sup" name="OPT_ID_926">2</span><span class="unicode-char">&#160;</span>=<span class="unicode-char">&#160;</span>11.5, <span class="ce_italic" name="OPT_ID_927">p</span><span class="unicode-char">&#160;</span>&lt;<span class="unicode-char">&#160;</span>0.001) higher sensitivity (73.7% as opposed to 64.1%).</div>
                    <div class="ce_para" id="p0085" name="OPT_ID_928">In primary syphilis (<a title="tbl4" style="color:blue" class="ce_cross-ref" name="OPT_ID_929">Table<span class="unicode-char">&#160;</span>4</a>), the sensitivities (% sensitivity, 95% CI) of the Pathozyme (89.8%, 79.2<span class="unicode-char">&#8211;</span>96.2%) and the Euroimmun test (81.4%, 69.1<span class="unicode-char">&#8211;</span>90.3%) were significantly higher than the sensitivities of the VDRL (61%, 47.4<span class="unicode-char">&#8211;</span>73.5%) and the modified recomWell test (62.7%, 49.2<span class="unicode-char">&#8211;</span>75.0%) as assessed by the McNemar <span class="ce_italic" name="OPT_ID_930"><span class="unicode-char">&#967;</span></span><span class="ce_sup" name="OPT_ID_931"><span class="ce_italic" name="OPT_ID_932">2</span></span> test (<span class="ce_italic" name="OPT_ID_933"><span class="unicode-char">&#967;</span></span><span class="ce_sup" name="OPT_ID_934"><span class="ce_italic" name="OPT_ID_935">2</span></span><span class="unicode-char">&#160;</span>&gt;<span class="unicode-char">&#160;</span>3.841, <span class="ce_italic" name="OPT_ID_936">p</span><span class="unicode-char">&#160;</span>&lt;<span class="unicode-char">&#160;</span>0.05).<a title="bib16" style="color:blue" class="ce_cross-ref" name="OPT_ID_937"><span class="ce_sup" name="OPT_ID_938">16</span></a></div>
                    <div class="ce_para" id="p0090" name="OPT_ID_939">Twenty-three out of 59 primary syphilis patients had a negative VDRL. These patients probably had early infection as the TPPA titres (median 1:320, interquartile range &lt;1:80<span class="unicode-char">&#8211;</span>1:320) were also low. In this group, IgM-specific Pathozyme, modified recomWell, and Euroimmun tests were positive in 22/23, 10/23, and 17/23 cases, respectively. Detailed results of seven patients with indeterminate TPPA are summarized in <a title="tbl5" style="color:blue" class="ce_cross-ref" name="OPT_ID_940">Table<span class="unicode-char">&#160;</span>5</a><span class="ce_float-anchor" refid="tbl5" name="OPT_ID_941"></span>; in all of them syphilis was confirmed with later control sera, i.e., TPPA became positive and IgM EIA tests decreased after therapy. It is therefore believed that they had very early infection. Pathozyme, modified recomWell, and Euroimmun tests were positive or equivocal in 7/7, 2/7 and 3/7 cases, respectively.</div>
                    <div class="table" id="tbl5" name="OPT_ID_668">
                        <div class="tablecaption"><span class="ce_label" name="OPT_ID_669">Table<span class="unicode-char">&#160;</span>5</span><span class="x">&#160;</span><span class="ce_caption" id="cap0030" name="OPT_ID_670"><span class="ce_simple-para" id="tspara0045" name="OPT_ID_671">Detailed results of seven primary syphilis patients with indeterminate TPPA result.</span></span>
                        </div>
                        <table border="0" frame="hsides" class="topbot" name="OPT_ID_672">
                            <col width="5%"></col>
                            <col width="17%"></col>
                            <col width="5%"></col>
                            <col width="6%"></col>
                            <col width="7%"></col>
                            <col width="6%"></col>
                            <col width="9%"></col>
                            <col width="9%"></col>
                            <col width="14%"></col>
                            <col width="16%"></col>
                            <thead title="thead" name="OPT_ID_683">
                                <tr title="table-row" name="OPT_ID_684">
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_685">No.</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_686">Clinical data</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_687">HIV</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_688">TPPA</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_689">FTA-ABS</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_690">VDRL</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_691">Pathozyme</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_692">Euroimmun</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_693">Modified recomWell</td>
                                    <td class="td" title="table-head" align="" valign="top" name="OPT_ID_694">Remarks</td>
                                </tr>
                            </thead>
                            <tbody title="tbody" name="OPT_ID_695">
                                <tr title="table-row" name="OPT_ID_696">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_697">1</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_698">Genital ulcer</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_699">ND</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_700"><span class="unicode-char">&#177;</span></td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_701"><span class="unicode-char">&#177;</span></td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_702">1:2</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_703" char="(">+(1.12)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_704" char="(">+(&gt;3.5)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_705" char="(">+(30.9)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_706">Therapy control (3-month): TPPA 1:640; VDRL<span class="unicode-char1">&#8722;</span>; Euroimmun 1.18</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_707">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_708">2</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_709">Genital ulcer, inguinal lymphadenopathy</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_710"><span class="unicode-char">&#8211;</span></td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_711"><span class="unicode-char">&#177;</span></td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_712"><span class="unicode-char">&#177;</span></td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_713"><span class="unicode-char1">&#8722;</span></td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_714" char="(">+(&gt;3.5)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_715" char="(">+(&gt;3.5)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_716" char="(">+(67.4)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_717">Therapy control (9-month): TPPA 1:320, VDRL<span class="unicode-char1">&#8722;</span>; Euroimmun 0.66</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_718">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_719">3</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_720">Erythematous papules and erosions on penis shaft (suggestive for HSV)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_721"><span class="unicode-char1">&#8722;</span></td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_722"><span class="unicode-char">&#177;</span></td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_723">ND</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_724"><span class="unicode-char1">&#8722;</span></td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_725" char="(">+(2.76)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_726" char="("><span class="unicode-char1">&#8722;</span>(0.46)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_727" char="("><span class="unicode-char1">&#8722;</span>(3.7)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_728">No therapy. Diagnosis of syphilis 3 months later: TPPA 1:2560; VDRL<span class="unicode-char">&#177;</span>; Pathozyme 2.61</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_729">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_730">4</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_731">Erythematous maculae on sulcus coronaries</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_732"><span class="unicode-char1">&#8722;</span></td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_733"><span class="unicode-char">&#177;</span></td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_734"><span class="unicode-char">&#177;</span></td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_735"><span class="unicode-char1">&#8722;</span></td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_736" char="(">+(1.35)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_737" char="("><span class="unicode-char1">&#8722;</span>(0.26)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_738" char="("><span class="unicode-char1">&#8722;</span>(4.1)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_739">Therapy control (2-month): TPPA 1:80; VDRL<span class="unicode-char1">&#8722;</span>; Pathozyme 1.36; clinically healed</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_740">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_741">5</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_742">No symptoms, several risk situations, i.e. unprotected sexual intercourse</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_743">+</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_744"><span class="unicode-char">&#177;</span></td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_745"><span class="unicode-char">&#177;</span></td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_746"><span class="unicode-char1">&#8722;</span></td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_747" char="(">+(1.28)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_748" char="("><span class="unicode-char">&#177;</span>(1.09)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_749" char="("><span class="unicode-char1">&#8722;</span>(9.7)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_750">Control serum 2 weeks later: TPPA 1:320; VDRL 1:8; Pathozyme 2.88</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_751">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_752">6</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_753">No symptoms, risk situation, i.e. sexual partner with syphilis</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_754">+</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_755"><span class="unicode-char">&#177;</span></td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_756"><span class="unicode-char">&#177;</span></td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_757"><span class="unicode-char1">&#8722;</span></td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_758" char="(">+(1.56)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_759" char="("><span class="unicode-char1">&#8722;</span>(0.27)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_760" char="("><span class="unicode-char1">&#8722;</span>(5.5)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_761">Therapy control (3-month): TPPA 1:160; VDRL<span class="unicode-char1">&#8722;</span>; Pathozyme 0.54</td>
                                </tr>
                                <tr title="table-row" name="OPT_ID_762">
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_763">7</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_764">Chlamydial and gonococcal proctitis, no syphilis symptoms</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_765">+</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_766"><span class="unicode-char">&#177;</span></td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_767">+</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_768"><span class="unicode-char1">&#8722;</span></td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_769" char="(">+(1.63)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_770" char="("><span class="unicode-char1">&#8722;</span>(0.66)</td>
                                    <td class="td" title="table-entry" align="char" valign="top" name="OPT_ID_771" char="("><span class="unicode-char1">&#8722;</span>(10.2)</td>
                                    <td class="td" title="table-entry" align="" valign="top" name="OPT_ID_772">No therapy. Diagnosis of syphilis 2 month later: TPPA 1:2560; VDRL 1:16; Pathozyme 2.37</td>
                                </tr>
                            </tbody>
                        </table>
                        <div class="ce_legend" name="OPT_ID_773">
                            <div title="legend" id="tspara0050" name="OPT_ID_774">TPPA, <span class="ce_italic" name="OPT_ID_775">Treponema pallidum</span> particle agglutination; FTA-ABS, fluorescent treponemal antibody<span class="unicode-char">&#8211;</span>absorption; VDRL, Venereal Disease Research Laboratory; and ND, not done.</div>
                        </div>
                    </div>
                    <div class="ce_para" id="p0095" name="OPT_ID_942">The specificity of all tests ranged from 91.4 to 100% (<a title="tbl3" style="color:blue" class="ce_cross-ref" name="OPT_ID_943">Tables<span class="unicode-char">&#160;</span>3</a> and <a title="tbl4" style="color:blue" class="ce_cross-ref" name="OPT_ID_944">4</a>). All investigated specific IgM tests showed some cross-reactivity, especially the Euroimmun Anti-Treponema-pallidum-ELISA had difficulties with sera containing IgM antibodies against human Herpes viruses (7/10 anti-Epstein<span class="unicode-char">&#8211;</span>Barr virus IgM sera and 3/10 anti-Cytomegalovirus IgM sera).</div>
                </div>
                <div class="ce_section" id="sec4" name="OPT_ID_945">
                    <div class="sectionline_opt"><span class="ce_section-title" name="OPT_ID_946">Discussion</span></div>
                    <div class="ce_para" id="p0100" name="OPT_ID_947">The clinical and laboratory diagnosis of primary syphilis can be difficult. Usually one or multiple, painless and indurate ulcers develop at the site of infection. However, the lesion may be atypical,<a title="bib1" style="color:blue" class="ce_cross-refs" name="OPT_ID_948"><span class="ce_sup" name="OPT_ID_949">1,17</span></a> e.g., (i) only a papular lesion may develop, (ii) it may be inconspicuous, (iii) it does not develop in every case, (iv) a syphilitic balanitis of Follman may be the only clinical expression. Patients might also seek medical advice after risk situations in the incubation period before development of clinical symptoms. Besides dark-field microscopy, which requires experienced staff and is labour intensive, and molecular tests, which are not yet generally used and are expensive, serological tests remain the most important tool for diagnosing syphilis. In the present study, and in those of others,<a title="bib4" style="color:blue" class="ce_cross-refs" name="OPT_ID_950"><span class="ce_sup" name="OPT_ID_951">4,5</span></a> the TPPA was the most sensitive single test in all stages of disease, confirming its suitability as a screening test.<a title="bib1" style="color:blue" class="ce_cross-ref" name="OPT_ID_952"><span class="ce_sup" name="OPT_ID_953">1</span></a> The VDRL test sensitivity was only 61% for primary syphilis, which is similar to what we found previously (58%)<a title="bib2" style="color:blue" class="ce_cross-ref" name="OPT_ID_954"><span class="ce_sup" name="OPT_ID_955">2</span></a> but somewhat lower than what other studies reported (66<span class="unicode-char">&#8211;</span>87%).<a title="bib3" style="color:blue" class="ce_cross-refs" name="OPT_ID_956"><span class="ce_sup" name="OPT_ID_957">3,18,19</span></a> The sensitivity of the IgM-specific syphilis EIA assays for detecting primary syphilis was 89.8% for the Pathozyme Syphilis M Capture (Omega Diagnostics) test and 81.4% for the Anti-Treponema-pallidum-ELISA (IgM; Euroimmun). This was significantly higher than 62.7% of the modified recomWell Treponema IgM (Mikrogen) or 61% of the VDRL test. In secondary syphilis which corresponds to the hematogenic spreading of the pathogen throughout the entire body the EIAs had their highest sensitivities, whereas in latent syphilis which clinically is a silent period IgM EIA values were low and many samples were negative.</div>
                    <div class="ce_para" id="p0105" name="OPT_ID_958">Most interestingly is the group of primary syphilis patients with negative VDRL. These 23/59 (39%) cases all would have been missed when the VDRL was used as the only first-line screening test as previously recommended in the United States.<a title="bib18" style="color:blue" class="ce_cross-refs" name="OPT_ID_959"><span class="ce_sup" name="OPT_ID_960">18,20</span></a> In this subgroup, the TPPA was positive in 17/23 and indeterminate in 6/23 cases. TPPA alone would have allowed diagnosing present or past syphilis infection in these cases (still, the six indeterminate cases would have been doubtful requiring confirmation with second samples). However, the combination of TPPA and IgM-specific EIA assays allowed correct diagnosis of early primary syphilis in 22/23 and 17/23 cases with the Pathozyme and the Euroimmun assay, respectively. The Pathozyme assay was even positive in seven cases with presumed very early infection with some patients eventually still being in the incubation phase (<a title="tbl5" style="color:blue" class="ce_cross-ref" name="OPT_ID_961">Table<span class="unicode-char">&#160;</span>5</a>). It has been previously shown that a specific IgM EIA may be the only positive test in early infection.<a title="bib2" style="color:blue" class="ce_cross-refs" name="OPT_ID_962"><span class="ce_sup" name="OPT_ID_963">2,5</span></a> It is therefore suggested that in cases of suspected early infection specific IgM EIAs should be used in addition to other screening tests.<a title="bib1" style="color:blue" class="ce_cross-ref" name="OPT_ID_964"><span class="ce_sup" name="OPT_ID_965">1</span></a> It is important that clinicians communicate the suspicion of early infection to the laboratory in order that an IgM EIA is utilized.</div>
                    <div class="ce_para" id="p0110" name="OPT_ID_966">Most previous studies investigating IgM-specific commercial assays have examined the Mercia Syphilis M EIA (Microgen Products Ltd),<a title="bib4" style="color:blue" class="ce_cross-refs" name="OPT_ID_967"><span class="ce_sup" name="OPT_ID_968">4,5,8<span class="unicode-char">&#8211;</span>12</span></a> in one study the Eti-syphilis-M was analysed (DiaSorin).<a title="bib7" style="color:blue" class="ce_cross-ref" name="OPT_ID_969"><span class="ce_sup" name="OPT_ID_970">7</span></a> The reported sensitivities are similar to the ones found here, for primary syphilis they were in the range of 82<span class="unicode-char">&#8211;</span>94% and for secondary syphilis in the range of 60<span class="unicode-char">&#8211;</span>100%. For latent syphilis the sensitivity was dependent on whether early (56<span class="unicode-char">&#8211;</span>87%) or late (0<span class="unicode-char">&#8211;</span>50%) latent cases were examined. In one previous study the recomWell Treponema IgM assay was investigated,<a title="bib13" style="color:blue" class="ce_cross-ref" name="OPT_ID_971"><span class="ce_sup" name="OPT_ID_972">13</span></a> the sensitivity in 19 primary syphilis cases was 89.5% which is higher than in the present work. However, the assay was negative in all samples of later stages of syphilis. Schmidt et<span class="unicode-char">&#160;</span>al.<a title="bib10" style="color:blue" class="ce_cross-ref" name="OPT_ID_973"><span class="ce_sup" name="OPT_ID_974">10</span></a> evaluated nine commercially available EIAs with a panel of 52 highly selected sera from primary syphilis patients, all negative with the microhemagglutination test for <span class="ce_italic" name="OPT_ID_975">T. pallidum</span>. Eight assays were designed to detect IgG alone or in combination with IgM antibodies. Most interestingly, the one assay detecting only IgM antibodies (Mercia Syphilis M EIA) demonstrated the highest sensitivity (86.5%) as compared to the other tests (22.6<span class="unicode-char">&#8211;</span>76.9%).</div>
                    <div class="ce_para" id="p0115" name="OPT_ID_976">Remarkable is the fact that all these previous studies except two did not report the specificity. Ijsselmuiden et<span class="unicode-char">&#160;</span>al.<a title="bib8" style="color:blue" class="ce_cross-ref" name="OPT_ID_977"><span class="ce_sup" name="OPT_ID_978">8</span></a> tested 48 samples of mainly treated syphilis patients and non-infected neonates with a specificity of 98% and Sambri et<span class="unicode-char">&#160;</span>al.<a title="bib13" style="color:blue" class="ce_cross-ref" name="OPT_ID_979"><span class="ce_sup" name="OPT_ID_980">13</span></a> tested 200 samples from blood donors and 60 samples from patients with possibly cross-reactive conditions (e.g. Lyme disease, mononucleosis, pregnancy) with 100% specificity. In the present study, 151 sera including 71 potentially cross-reactive samples were investigated for testing the specificity. Except for the Euroimmun assay which had some difficulties with sera which were positive for IgM antibodies against human Herpes viruses, all other assays showed specificities of 95.4<span class="unicode-char">&#8211;</span>100%.</div>
                    <div class="ce_para" id="p0120" name="OPT_ID_981">For monitoring the treatment response primarily non-treponemal tests such the VDRL or the RPR are recommended.<a title="bib1" style="color:blue" class="ce_cross-refs" name="OPT_ID_982"><span class="ce_sup" name="OPT_ID_983">1,3</span></a> It has been shown previously that specific IgM EIAs are a reliable supplement<a title="bib2" style="color:blue" class="ce_cross-refs" name="OPT_ID_984"><span class="ce_sup" name="OPT_ID_985">2,21,22</span></a> and this might be especially valuable in cases with an initially negative VDRL test (mainly primary syphilis cases) and in case of a slow decline or persisting low VDRL reactivity despite adequate therapy. However, it has to be noted that response rate may be different among different commercial IgM EIAs and also different as compared to the VDRL. Studies which used the Mercia Syphilis M EIA reported negative test results one year after treatment in 92<span class="unicode-char">&#8211;</span>100% of patients presenting with early syphilis<a title="bib21" style="color:blue" class="ce_cross-refs" name="OPT_ID_986"><span class="ce_sup" name="OPT_ID_987">21,22</span></a> - as compared to 62<span class="unicode-char">&#8211;</span>87% in a study using the Pathozyme test.<a title="bib2" style="color:blue" class="ce_cross-ref" name="OPT_ID_988"><span class="ce_sup" name="OPT_ID_989">2</span></a></div>
                    <div class="ce_para" id="p0125" name="OPT_ID_990">All three IgM tests are easy to perform and do not require special equipment or special skills and knowledge of the staff. They have total incubation times of 2<span class="unicode-char">&#8211;</span>2.5<span class="unicode-char">&#160;</span>h and can be executed routinely within half a day. The tests differ, however, in their accuracy with the recomWell being the least sensitive. The recomWell assay is an indirect <span class="unicode-char">&#8216;</span>sandwich<span class="unicode-char">&#8217;</span> EIA. In this kind of assay patients IgG antibodies are usually precipitated with an anti-human-IgG antibody to avoid a competition with IgM antibodies in binding to the recombinant antigens what can cause a false-negative result. This step is missing in the recomWell procedure. Therefore, a modified recomWell protocol precipitating interfering IgG antibodies was tested. The sensitivity thus significantly increased from 64.1 to 73.7%. This demonstrates that the pre-adsorption of interfering IgG antibodies increases the performance. With some optimization of the protocol the sensitivity might be increased even more.</div>
                    <div class="ce_para" id="p0130" name="OPT_ID_991">A limitation of this study is the fact that the sera were stored at <span class="unicode-char1">&#8722;</span>20<span class="unicode-char">&#160;</span><span class="unicode-char">&#176;</span>C until testing with the Euroimmun and the recomWell assay. It cannot be entirely excluded that this might have influenced the result in some cases.</div>
                    <div class="ce_para" id="p0135" name="OPT_ID_992">In summary, specific syphilis IgM EIA assays are highly sensitive in primary syphilis and are specific. It is suggested that in cases of suspected early infection specific IgM EIAs should be used in addition to other screening tests. Additionally, they allow differentiation of active and past infection and may be used as supplement for monitoring treatment response. EIAs from different manufacturers vary in their performance.</div>
                </div>
                <div class="ce_section" id="sec5" name="OPT_ID_993">
                    <div class="sectionline_opt"><span class="ce_section-title" name="OPT_ID_994">Addendum</span></div>
                    <div class="ce_para" id="p0140" name="OPT_ID_995">During the course of this study Omega Diagnostics informed that the Pathozyme Syphilis M Capture test is suspended from production until further notice.</div>
                </div>
                <div class="ce_section" id="sec6" name="OPT_ID_996">
                    <div class="sectionline_opt"><span class="ce_section-title" name="OPT_ID_997">Conflict of interest</span></div>
                    <div class="ce_para" id="p0145" name="OPT_ID_998">Mikrogen, Neuried, Germany and Pharma Consulting Marion Senn GmbH, Burgdorf, Switzerland sponsored 50% and 25% of costs of the recomWell Treponema IgM (Mikrogen) tests, respectively; Euroimmun Schweiz AG, Luzern, Switzerland has sponsored all Euroimmun Anti-Treponema-pallidum-ELISA (IgM) tests. The author has served as speaker for Euroimmun Switzerland and has received travel grants from Euroimmun Switzerland. No company had influence on the design of the study, interpretation of results, the final manuscript or any other part of the study.</div>
                </div>
            </div>
            <div class="ce_acknowledgment" name="OPT_ID_999" id="ce_acknowledgment1"><span class="ce_section-title" name="OPT_ID_1000">Acknowledgements</span>
                <div class="ce_para" id="p0150" name="OPT_ID_1001">I deeply appreciate the technical assistance of Tamara Eicher. I thank Thomas K<span class="unicode-char">&#252;</span>ndig for critical review of the manuscript, Nicole Graf for statistical advice, and Walter Bossart and Reinhard Zbinden for providing potentially cross-reactive serum samples.</div>
            </div>
        </div>
        <div class="tail" name="OPT_ID_1002">
            <div class="ce_bibliography" id="cebib0010" name="OPT_ID_1003"><span class="ce_section-title" name="OPT_ID_1004">References</span>
                <div class="ce_bibliography-sec" id="cebibsec0010" name="OPT_ID_1005">
                    <div class="ce_bib-reference" id="bib1" name="OPT_ID_1006"><span class="ce_label" name="OPT_ID_1007">1</span><span class="x">.&#160;</span><span class="sb_reference" name="OPT_ID_1008"><span class="sb_contribution" name="OPT_ID_1009"><span class="sb_authors aug" name="OPT_ID_1010"><span class="sb_author au" name="OPT_ID_1011"><span class="ce_given-name fnm" name="OPT_ID_1012">P.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1013">French</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1014"><span class="ce_given-name fnm" name="OPT_ID_1015">M.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1016">Gomberg</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1017"><span class="ce_given-name fnm" name="OPT_ID_1018">M.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1019">Janier</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1020"><span class="ce_given-name fnm" name="OPT_ID_1021">B.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1022">Schmidt</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1023"><span class="ce_given-name fnm" name="OPT_ID_1024">P.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1025">van Voorst Vader</span></span><span class="x"> and </span><span class="sb_author au" name="OPT_ID_1026"><span class="ce_given-name fnm" name="OPT_ID_1027">H.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1028">Young</span></span><span class="x">, </span></span><span class="sb_title atl" name="OPT_ID_1029"><span class="sb_maintitle" name="OPT_ID_1030">IUSTI: 2008 European guidelines on the management of syphilis</span><span class="x">, </span></span>
                        </span><span class="sb_host" name="OPT_ID_1031"><span class="sb_issue" name="OPT_ID_1032"><span class="sb_series" name="OPT_ID_1033"><span class="sb_title sitl" name="OPT_ID_1034"><span class="sb_maintitle" name="OPT_ID_1035">Int J STD AIDS</span></span><span class="x">&#160;</span><span class="sb_volume-nr vol" name="OPT_ID_1036">20</span><span class="x">&#160;</span></span><span class="sb_issue-nr iss" name="OPT_ID_1037"><span class="x">(</span>5<span class="x">), </span></span><span class="sb_date date" name="OPT_ID_1038">2009</span><span class="x">, </span></span><span class="sb_pages pages" name="OPT_ID_1039"><span class="sb_first-page fpage" name="OPT_ID_1040">300</span><span class="sb_last-page lpage" name="OPT_ID_1041"><span class="x">&#8211;</span>309</span>
                        </span>
                        </span><span class="x">.</span></span>
                    </div>
                    <div class="ce_bib-reference" id="bib2" name="OPT_ID_1042"><span class="ce_label" name="OPT_ID_1043">2</span><span class="x">.&#160;</span><span class="sb_reference" name="OPT_ID_1044"><span class="sb_contribution" name="OPT_ID_1045"><span class="sb_authors aug" name="OPT_ID_1046"><span class="sb_author au" name="OPT_ID_1047"><span class="ce_given-name fnm" name="OPT_ID_1048">D.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1049">Fr<span class="unicode-char">&#246;</span>hlich Knaute</span>
                        </span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1050"><span class="ce_given-name fnm" name="OPT_ID_1051">N.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1052">Graf</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1053"><span class="ce_given-name fnm" name="OPT_ID_1054">S.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1055">Lautenschlager</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1056"><span class="ce_given-name fnm" name="OPT_ID_1057">R.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1058">Weber</span></span><span class="x"> and </span><span class="sb_author au" name="OPT_ID_1059"><span class="ce_given-name fnm" name="OPT_ID_1060">P.P.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1061">Bosshard</span></span><span class="x">, </span></span><span class="sb_title atl" name="OPT_ID_1062"><span class="sb_maintitle" name="OPT_ID_1063">Serological response to treatment of syphilis according to disease stage and HIV status</span><span class="x">, </span></span>
                        </span><span class="sb_host" name="OPT_ID_1064"><span class="sb_issue" name="OPT_ID_1065"><span class="sb_series" name="OPT_ID_1066"><span class="sb_title sitl" name="OPT_ID_1067"><span class="sb_maintitle" name="OPT_ID_1068">Clin Infect Dis</span></span><span class="x">&#160;</span></span><span class="sb_date date" name="OPT_ID_1069">2012</span><span class="x">, </span></span><span class="ce_doi" name="OPT_ID_1070"><span class="x">http://dx.doi.org/</span>10.1093/cid/cis757</span>
                        </span><span class="x">.</span></span>
                    </div>
                    <div class="ce_bib-reference" id="bib3" name="OPT_ID_1071"><span class="ce_label" name="OPT_ID_1072">3</span><span class="x">.&#160;</span><span class="sb_reference" name="OPT_ID_1073"><span class="sb_contribution" name="OPT_ID_1074"><span class="sb_authors aug" name="OPT_ID_1075"><span class="sb_author au" name="OPT_ID_1076"><span class="ce_given-name fnm" name="OPT_ID_1077">S.A.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1078">Larsen</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1079"><span class="ce_given-name fnm" name="OPT_ID_1080">B.M.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1081">Steiner</span></span><span class="x"> and </span><span class="sb_author au" name="OPT_ID_1082"><span class="ce_given-name fnm" name="OPT_ID_1083">A.H.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1084">Rudolph</span></span><span class="x">, </span></span><span class="sb_title atl" name="OPT_ID_1085"><span class="sb_maintitle" name="OPT_ID_1086">Laboratory diagnosis and interpretation of tests for syphilis</span><span class="x">, </span></span>
                        </span><span class="sb_host" name="OPT_ID_1087"><span class="sb_issue" name="OPT_ID_1088"><span class="sb_series" name="OPT_ID_1089"><span class="sb_title sitl" name="OPT_ID_1090"><span class="sb_maintitle" name="OPT_ID_1091">Clin Microbiol Rev</span></span><span class="x">&#160;</span><span class="sb_volume-nr vol" name="OPT_ID_1092">8</span><span class="x">&#160;</span></span><span class="sb_issue-nr iss" name="OPT_ID_1093"><span class="x">(</span>1<span class="x">), </span></span><span class="sb_date date" name="OPT_ID_1094">1995</span><span class="x">, </span></span><span class="sb_pages pages" name="OPT_ID_1095"><span class="sb_first-page fpage" name="OPT_ID_1096">1</span><span class="sb_last-page lpage" name="OPT_ID_1097"><span class="x">&#8211;</span>21</span>
                        </span>
                        </span><span class="x">.</span></span>
                    </div>
                    <div class="ce_bib-reference" id="bib4" name="OPT_ID_1098"><span class="ce_label" name="OPT_ID_1099">4</span><span class="x">.&#160;</span><span class="sb_reference" name="OPT_ID_1100"><span class="sb_contribution" name="OPT_ID_1101"><span class="sb_authors aug" name="OPT_ID_1102"><span class="sb_author au" name="OPT_ID_1103"><span class="ce_given-name fnm" name="OPT_ID_1104">K.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1105">Manavi</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1106"><span class="ce_given-name fnm" name="OPT_ID_1107">H.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1108">Young</span></span><span class="x"> and </span><span class="sb_author au" name="OPT_ID_1109"><span class="ce_given-name fnm" name="OPT_ID_1110">A.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1111">McMillan</span></span><span class="x">, </span></span><span class="sb_title atl" name="OPT_ID_1112"><span class="sb_maintitle" name="OPT_ID_1113">The sensitivity of syphilis assays in detecting different stages of early syphilis</span><span class="x">, </span></span>
                        </span><span class="sb_host" name="OPT_ID_1114"><span class="sb_issue" name="OPT_ID_1115"><span class="sb_series" name="OPT_ID_1116"><span class="sb_title sitl" name="OPT_ID_1117"><span class="sb_maintitle" name="OPT_ID_1118">Int J STD AIDS</span></span><span class="x">&#160;</span><span class="sb_volume-nr vol" name="OPT_ID_1119">17</span><span class="x">&#160;</span></span><span class="sb_issue-nr iss" name="OPT_ID_1120"><span class="x">(</span>11<span class="x">), </span></span><span class="sb_date date" name="OPT_ID_1121">2006</span><span class="x">, </span></span><span class="sb_pages pages" name="OPT_ID_1122"><span class="sb_first-page fpage" name="OPT_ID_1123">768</span><span class="sb_last-page lpage" name="OPT_ID_1124"><span class="x">&#8211;</span>771</span>
                        </span>
                        </span><span class="x">.</span></span>
                    </div>
                    <div class="ce_bib-reference" id="bib5" name="OPT_ID_1125"><span class="ce_label" name="OPT_ID_1126">5</span><span class="x">.&#160;</span><span class="sb_reference" name="OPT_ID_1127"><span class="sb_contribution" name="OPT_ID_1128"><span class="sb_authors aug" name="OPT_ID_1129"><span class="sb_author au" name="OPT_ID_1130"><span class="ce_given-name fnm" name="OPT_ID_1131">A.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1132">McMillan</span></span><span class="x"> and </span><span class="sb_author au" name="OPT_ID_1133"><span class="ce_given-name fnm" name="OPT_ID_1134">H.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1135">Young</span></span><span class="x">, </span></span><span class="sb_title atl" name="OPT_ID_1136"><span class="sb_maintitle" name="OPT_ID_1137">Qualitative and quantitative aspects of the serological diagnosis of early syphilis</span><span class="x">, </span></span>
                        </span><span class="sb_host" name="OPT_ID_1138"><span class="sb_issue" name="OPT_ID_1139"><span class="sb_series" name="OPT_ID_1140"><span class="sb_title sitl" name="OPT_ID_1141"><span class="sb_maintitle" name="OPT_ID_1142">Int J STD AIDS</span></span><span class="x">&#160;</span><span class="sb_volume-nr vol" name="OPT_ID_1143">19</span><span class="x">&#160;</span></span><span class="sb_issue-nr iss" name="OPT_ID_1144"><span class="x">(</span>9<span class="x">), </span></span><span class="sb_date date" name="OPT_ID_1145">2008</span><span class="x">, </span></span><span class="sb_pages pages" name="OPT_ID_1146"><span class="sb_first-page fpage" name="OPT_ID_1147">620</span><span class="sb_last-page lpage" name="OPT_ID_1148"><span class="x">&#8211;</span>624</span>
                        </span>
                        </span><span class="x">.</span></span>
                    </div>
                    <div class="ce_bib-reference" id="bib6" name="OPT_ID_1149"><span class="ce_label" name="OPT_ID_1150">6</span><span class="x">.&#160;</span><span class="sb_reference" name="OPT_ID_1151"><span class="sb_contribution" name="OPT_ID_1152"><span class="sb_authors aug" name="OPT_ID_1153"><span class="sb_author au" name="OPT_ID_1154"><span class="ce_given-name fnm" name="OPT_ID_1155">R.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1156">Shannon</span></span><span class="x"> and </span><span class="sb_author au" name="OPT_ID_1157"><span class="ce_given-name fnm" name="OPT_ID_1158">S.D.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1159">Booth</span></span><span class="x">, </span></span><span class="sb_title atl" name="OPT_ID_1160"><span class="sb_maintitle" name="OPT_ID_1161">The pattern of immunological responses at various stages of syphilis</span><span class="x">, </span></span>
                        </span><span class="sb_host" name="OPT_ID_1162"><span class="sb_issue" name="OPT_ID_1163"><span class="sb_series" name="OPT_ID_1164"><span class="sb_title sitl" name="OPT_ID_1165"><span class="sb_maintitle" name="OPT_ID_1166">Br J Vener Dis</span></span><span class="x">&#160;</span><span class="sb_volume-nr vol" name="OPT_ID_1167">53</span><span class="x">&#160;</span></span><span class="sb_issue-nr iss" name="OPT_ID_1168"><span class="x">(</span>5<span class="x">), </span></span><span class="sb_date date" name="OPT_ID_1169">1977</span><span class="x">, </span></span><span class="sb_pages pages" name="OPT_ID_1170"><span class="sb_first-page fpage" name="OPT_ID_1171">281</span><span class="sb_last-page lpage" name="OPT_ID_1172"><span class="x">&#8211;</span>286</span>
                        </span>
                        </span><span class="x">.</span></span>
                    </div>
                    <div class="ce_bib-reference" id="bib7" name="OPT_ID_1173"><span class="ce_label" name="OPT_ID_1174">7</span><span class="x">.&#160;</span><span class="sb_reference" name="OPT_ID_1175"><span class="sb_contribution" name="OPT_ID_1176"><span class="sb_authors aug" name="OPT_ID_1177"><span class="sb_author au" name="OPT_ID_1178"><span class="ce_given-name fnm" name="OPT_ID_1179">R.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1180">Castro</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1181"><span class="ce_given-name fnm" name="OPT_ID_1182">E.S.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1183">Prieto</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1184"><span class="ce_given-name fnm" name="OPT_ID_1185">I.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1186">Santo</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1187"><span class="ce_given-name fnm" name="OPT_ID_1188">J.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1189">Azevedo</span></span><span class="x"> and </span><span class="sb_author au" name="OPT_ID_1190"><span class="ce_given-name fnm" name="OPT_ID_1191">L.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1192">Exposto Fda</span></span><span class="x">, </span></span><span class="sb_title atl" name="OPT_ID_1193"><span class="sb_maintitle" name="OPT_ID_1194">Evaluation of an enzyme immunoassay technique for detection of antibodies against <span class="ce_italic" name="OPT_ID_1195">Treponema pallidum</span></span><span class="x">, </span></span>
                        </span><span class="sb_host" name="OPT_ID_1196"><span class="sb_issue" name="OPT_ID_1197"><span class="sb_series" name="OPT_ID_1198"><span class="sb_title sitl" name="OPT_ID_1199"><span class="sb_maintitle" name="OPT_ID_1200">J Clin Microbiol</span></span><span class="x">&#160;</span><span class="sb_volume-nr vol" name="OPT_ID_1201">41</span><span class="x">&#160;</span></span><span class="sb_issue-nr iss" name="OPT_ID_1202"><span class="x">(</span>1<span class="x">), </span></span><span class="sb_date date" name="OPT_ID_1203">2003</span><span class="x">, </span></span><span class="sb_pages pages" name="OPT_ID_1204"><span class="sb_first-page fpage" name="OPT_ID_1205">250</span><span class="sb_last-page lpage" name="OPT_ID_1206"><span class="x">&#8211;</span>253</span>
                        </span>
                        </span><span class="x">.</span></span>
                    </div>
                    <div class="ce_bib-reference" id="bib8" name="OPT_ID_1207"><span class="ce_label" name="OPT_ID_1208">8</span><span class="x">.&#160;</span><span class="sb_reference" name="OPT_ID_1209"><span class="sb_contribution" name="OPT_ID_1210"><span class="sb_authors aug" name="OPT_ID_1211"><span class="sb_author au" name="OPT_ID_1212"><span class="ce_given-name fnm" name="OPT_ID_1213">O.E.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1214">Ijsselmuiden</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1215"><span class="ce_given-name fnm" name="OPT_ID_1216">J.J.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1217">van der Sluis</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1218"><span class="ce_given-name fnm" name="OPT_ID_1219">A.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1220">Mulder</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1221"><span class="ce_given-name fnm" name="OPT_ID_1222">E.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1223">Stolz</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1224"><span class="ce_given-name fnm" name="OPT_ID_1225">K.P.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1226">Bolton</span></span><span class="x"> and </span><span class="sb_author au" name="OPT_ID_1227"><span class="ce_given-name fnm" name="OPT_ID_1228">R.V.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1229">van Eijk</span></span><span class="x">, </span></span><span class="sb_title atl" name="OPT_ID_1230"><span class="sb_maintitle" name="OPT_ID_1231">An IgM capture enzyme linked immunosorbent assay to detect IgM antibodies to treponemes in patients with syphilis</span><span class="x">, </span></span>
                        </span><span class="sb_host" name="OPT_ID_1232"><span class="sb_issue" name="OPT_ID_1233"><span class="sb_series" name="OPT_ID_1234"><span class="sb_title sitl" name="OPT_ID_1235"><span class="sb_maintitle" name="OPT_ID_1236">Genitourin Med</span></span><span class="x">&#160;</span><span class="sb_volume-nr vol" name="OPT_ID_1237">65</span><span class="x">&#160;</span></span><span class="sb_issue-nr iss" name="OPT_ID_1238"><span class="x">(</span>2<span class="x">), </span></span><span class="sb_date date" name="OPT_ID_1239">1989</span><span class="x">, </span></span><span class="sb_pages pages" name="OPT_ID_1240"><span class="sb_first-page fpage" name="OPT_ID_1241">79</span><span class="sb_last-page lpage" name="OPT_ID_1242"><span class="x">&#8211;</span>83</span>
                        </span>
                        </span><span class="x">.</span></span>
                    </div>
                    <div class="ce_bib-reference" id="bib9" name="OPT_ID_1243"><span class="ce_label" name="OPT_ID_1244">9</span><span class="x">.&#160;</span><span class="sb_reference" name="OPT_ID_1245"><span class="sb_contribution" name="OPT_ID_1246"><span class="sb_authors aug" name="OPT_ID_1247"><span class="sb_author au" name="OPT_ID_1248"><span class="ce_given-name fnm" name="OPT_ID_1249">J.C.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1250">Lefevre</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1251"><span class="ce_given-name fnm" name="OPT_ID_1252">M.A.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1253">Bertrand</span></span><span class="x"> and </span><span class="sb_author au" name="OPT_ID_1254"><span class="ce_given-name fnm" name="OPT_ID_1255">R.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1256">Bauriaud</span></span><span class="x">, </span></span><span class="sb_title atl" name="OPT_ID_1257"><span class="sb_maintitle" name="OPT_ID_1258">Evaluation of the Captia enzyme immunoassays for detection of immunoglobulins G and M to <span class="ce_italic" name="OPT_ID_1259">Treponema pallidum</span> in syphilis</span><span class="x">, </span></span>
                        </span><span class="sb_host" name="OPT_ID_1260"><span class="sb_issue" name="OPT_ID_1261"><span class="sb_series" name="OPT_ID_1262"><span class="sb_title sitl" name="OPT_ID_1263"><span class="sb_maintitle" name="OPT_ID_1264">J Clin Microbiol</span></span><span class="x">&#160;</span><span class="sb_volume-nr vol" name="OPT_ID_1265">28</span><span class="x">&#160;</span></span><span class="sb_issue-nr iss" name="OPT_ID_1266"><span class="x">(</span>8<span class="x">), </span></span><span class="sb_date date" name="OPT_ID_1267">1990</span><span class="x">, </span></span><span class="sb_pages pages" name="OPT_ID_1268"><span class="sb_first-page fpage" name="OPT_ID_1269">1704</span><span class="sb_last-page lpage" name="OPT_ID_1270"><span class="x">&#8211;</span>1707</span>
                        </span>
                        </span><span class="x">.</span></span>
                    </div>
                    <div class="ce_bib-reference" id="bib10" name="OPT_ID_1271"><span class="ce_label" name="OPT_ID_1272">10</span><span class="x">.&#160;</span><span class="sb_reference" name="OPT_ID_1273"><span class="sb_contribution" name="OPT_ID_1274"><span class="sb_authors aug" name="OPT_ID_1275"><span class="sb_author au" name="OPT_ID_1276"><span class="ce_given-name fnm" name="OPT_ID_1277">B.L.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1278">Schmidt</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1279"><span class="ce_given-name fnm" name="OPT_ID_1280">M.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1281">Edjlalipour</span></span><span class="x"> and </span><span class="sb_author au" name="OPT_ID_1282"><span class="ce_given-name fnm" name="OPT_ID_1283">A.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1284">Luger</span></span><span class="x">, </span></span><span class="sb_title atl" name="OPT_ID_1285"><span class="sb_maintitle" name="OPT_ID_1286">Comparative evaluation of nine different enzyme-linked immunosorbent assays for determination of antibodies against <span class="ce_italic" name="OPT_ID_1287">Treponema pallidum</span> in patients with primary syphilis</span><span class="x">, </span></span>
                        </span><span class="sb_host" name="OPT_ID_1288"><span class="sb_issue" name="OPT_ID_1289"><span class="sb_series" name="OPT_ID_1290"><span class="sb_title sitl" name="OPT_ID_1291"><span class="sb_maintitle" name="OPT_ID_1292">J Clin Microbiol</span></span><span class="x">&#160;</span><span class="sb_volume-nr vol" name="OPT_ID_1293">38</span><span class="x">&#160;</span></span><span class="sb_issue-nr iss" name="OPT_ID_1294"><span class="x">(</span>3<span class="x">), </span></span><span class="sb_date date" name="OPT_ID_1295">2000</span><span class="x">, </span></span><span class="sb_pages pages" name="OPT_ID_1296"><span class="sb_first-page fpage" name="OPT_ID_1297">1279</span><span class="sb_last-page lpage" name="OPT_ID_1298"><span class="x">&#8211;</span>1282</span>
                        </span>
                        </span><span class="x">.</span></span>
                    </div>
                    <div class="ce_bib-reference" id="bib11" name="OPT_ID_1299"><span class="ce_label" name="OPT_ID_1300">11</span><span class="x">.&#160;</span><span class="sb_reference" name="OPT_ID_1301"><span class="sb_contribution" name="OPT_ID_1302"><span class="sb_authors aug" name="OPT_ID_1303"><span class="sb_author au" name="OPT_ID_1304"><span class="ce_given-name fnm" name="OPT_ID_1305">H.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1306">Young</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1307"><span class="ce_given-name fnm" name="OPT_ID_1308">J.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1309">Pryde</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1310"><span class="ce_given-name fnm" name="OPT_ID_1311">L.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1312">Duncan</span></span><span class="x"> and </span><span class="sb_author au" name="OPT_ID_1313"><span class="ce_given-name fnm" name="OPT_ID_1314">J.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1315">Dave</span></span><span class="x">, </span></span><span class="sb_title atl" name="OPT_ID_1316"><span class="sb_maintitle" name="OPT_ID_1317">The architect syphilis assay for antibodies to <span class="ce_italic" name="OPT_ID_1318">Treponema pallidum</span>: an automated screening assay with high sensitivity in primary syphilis</span><span class="x">, </span></span>
                        </span><span class="sb_host" name="OPT_ID_1319"><span class="sb_issue" name="OPT_ID_1320"><span class="sb_series" name="OPT_ID_1321"><span class="sb_title sitl" name="OPT_ID_1322"><span class="sb_maintitle" name="OPT_ID_1323">Sex Transm Infect</span></span><span class="x">&#160;</span><span class="sb_volume-nr vol" name="OPT_ID_1324">85</span><span class="x">&#160;</span></span><span class="sb_issue-nr iss" name="OPT_ID_1325"><span class="x">(</span>1<span class="x">), </span></span><span class="sb_date date" name="OPT_ID_1326">2009</span><span class="x">, </span></span><span class="sb_pages pages" name="OPT_ID_1327"><span class="sb_first-page fpage" name="OPT_ID_1328">19</span><span class="sb_last-page lpage" name="OPT_ID_1329"><span class="x">&#8211;</span>23</span>
                        </span>
                        </span><span class="x">.</span></span>
                    </div>
                    <div class="ce_bib-reference" id="bib12" name="OPT_ID_1330"><span class="ce_label" name="OPT_ID_1331">12</span><span class="x">.&#160;</span><span class="sb_reference" name="OPT_ID_1332"><span class="sb_contribution" name="OPT_ID_1333"><span class="sb_authors aug" name="OPT_ID_1334"><span class="sb_author au" name="OPT_ID_1335"><span class="ce_given-name fnm" name="OPT_ID_1336">I.L.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1337">Tabidze</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1338"><span class="ce_given-name fnm" name="OPT_ID_1339">F.K.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1340">Lee</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1341"><span class="ce_given-name fnm" name="OPT_ID_1342">P.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1343">Tambe</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1344"><span class="ce_given-name fnm" name="OPT_ID_1345">E.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1346">Rocha</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1347"><span class="ce_given-name fnm" name="OPT_ID_1348">S.A.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1349">Larsen</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1350"><span class="ce_given-name fnm" name="OPT_ID_1351">B.J.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1352">Stoll</span></span><span class="x">, </span><span class="sb_et-al" name="OPT_ID_1353"><span class="x"> et&#160;al., </span></span>
                        </span><span class="sb_title atl" name="OPT_ID_1354"><span class="sb_maintitle" name="OPT_ID_1355">Enzyme-linked immunospot assay for the diagnosis of active <span class="ce_italic" name="OPT_ID_1356">Treponema pallidum</span> infection during the various stages of syphilis</span><span class="x">, </span></span>
                        </span><span class="sb_host" name="OPT_ID_1357"><span class="sb_issue" name="OPT_ID_1358"><span class="sb_series" name="OPT_ID_1359"><span class="sb_title sitl" name="OPT_ID_1360"><span class="sb_maintitle" name="OPT_ID_1361">Sex Transm Dis</span></span><span class="x">&#160;</span><span class="sb_volume-nr vol" name="OPT_ID_1362">26</span><span class="x">&#160;</span></span><span class="sb_issue-nr iss" name="OPT_ID_1363"><span class="x">(</span>8<span class="x">), </span></span><span class="sb_date date" name="OPT_ID_1364">1999</span><span class="x">, </span></span><span class="sb_pages pages" name="OPT_ID_1365"><span class="sb_first-page fpage" name="OPT_ID_1366">426</span><span class="sb_last-page lpage" name="OPT_ID_1367"><span class="x">&#8211;</span>430</span>
                        </span>
                        </span><span class="x">.</span></span>
                    </div>
                    <div class="ce_bib-reference" id="bib13" name="OPT_ID_1368"><span class="ce_label" name="OPT_ID_1369">13</span><span class="x">.&#160;</span><span class="sb_reference" name="OPT_ID_1370"><span class="sb_contribution" name="OPT_ID_1371"><span class="sb_authors aug" name="OPT_ID_1372"><span class="sb_author au" name="OPT_ID_1373"><span class="ce_given-name fnm" name="OPT_ID_1374">V.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1375">Sambri</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1376"><span class="ce_given-name fnm" name="OPT_ID_1377">A.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1378">Marangoni</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1379"><span class="ce_given-name fnm" name="OPT_ID_1380">M.A.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1381">Simone</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1382"><span class="ce_given-name fnm" name="OPT_ID_1383">A.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1384">D<span class="unicode-char">&#8217;</span>Antuono</span>
                        </span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1385"><span class="ce_given-name fnm" name="OPT_ID_1386">M.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1387">Negosanti</span></span><span class="x"> and </span><span class="sb_author au" name="OPT_ID_1388"><span class="ce_given-name fnm" name="OPT_ID_1389">R.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1390">Cevenini</span></span><span class="x">, </span></span><span class="sb_title atl" name="OPT_ID_1391"><span class="sb_maintitle" name="OPT_ID_1392">Evaluation of recomWell Treponema, a novel recombinant antigen-based enzyme-linked immunosorbent assay for the diagnosis of syphilis</span><span class="x">, </span></span>
                        </span><span class="sb_host" name="OPT_ID_1393"><span class="sb_issue" name="OPT_ID_1394"><span class="sb_series" name="OPT_ID_1395"><span class="sb_title sitl" name="OPT_ID_1396"><span class="sb_maintitle" name="OPT_ID_1397">Clin Microbiol Infect</span></span><span class="x">&#160;</span><span class="sb_volume-nr vol" name="OPT_ID_1398">7</span><span class="x">&#160;</span></span><span class="sb_issue-nr iss" name="OPT_ID_1399"><span class="x">(</span>4<span class="x">), </span></span><span class="sb_date date" name="OPT_ID_1400">2001</span><span class="x">, </span></span><span class="sb_pages pages" name="OPT_ID_1401"><span class="sb_first-page fpage" name="OPT_ID_1402">200</span><span class="sb_last-page lpage" name="OPT_ID_1403"><span class="x">&#8211;</span>205</span>
                        </span>
                        </span><span class="x">.</span></span>
                    </div>
                    <div class="ce_bib-reference" id="bib14" name="OPT_ID_1404"><span class="ce_label" name="OPT_ID_1405">14</span><span class="x">.&#160;</span><span class="sb_reference" name="OPT_ID_1406"><span class="sb_contribution" name="OPT_ID_1407"><span class="sb_authors aug" name="OPT_ID_1408"><span class="sb_author au" name="OPT_ID_1409"><span class="ce_given-name fnm" name="OPT_ID_1410">S.A.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1411">Rawstron</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1412"><span class="ce_given-name fnm" name="OPT_ID_1413">S.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1414">Mehta</span></span><span class="x"> and </span><span class="sb_author au" name="OPT_ID_1415"><span class="ce_given-name fnm" name="OPT_ID_1416">K.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1417">Bromberg</span></span><span class="x">, </span></span><span class="sb_title atl" name="OPT_ID_1418"><span class="sb_maintitle" name="OPT_ID_1419">Evaluation of a Treponema pallidum-specific IgM enzyme immunoassay and <span class="ce_italic" name="OPT_ID_1420">Treponema pallidum</span> western blot antibody detection in the diagnosis of maternal and congenital syphilis</span><span class="x">, </span></span>
                        </span><span class="sb_host" name="OPT_ID_1421"><span class="sb_issue" name="OPT_ID_1422"><span class="sb_series" name="OPT_ID_1423"><span class="sb_title sitl" name="OPT_ID_1424"><span class="sb_maintitle" name="OPT_ID_1425">Sex Transm Dis</span></span><span class="x">&#160;</span><span class="sb_volume-nr vol" name="OPT_ID_1426">31</span><span class="x">&#160;</span></span><span class="sb_issue-nr iss" name="OPT_ID_1427"><span class="x">(</span>2<span class="x">), </span></span><span class="sb_date date" name="OPT_ID_1428">2004</span><span class="x">, </span></span><span class="sb_pages pages" name="OPT_ID_1429"><span class="sb_first-page fpage" name="OPT_ID_1430">123</span><span class="sb_last-page lpage" name="OPT_ID_1431"><span class="x">&#8211;</span>126</span>
                        </span>
                        </span><span class="x">.</span></span>
                    </div>
                    <div class="ce_bib-reference" id="bib15" name="OPT_ID_1432"><span class="ce_label" name="OPT_ID_1433">15</span><span class="x">.&#160;</span><span class="sb_reference" name="OPT_ID_1434"><span class="sb_contribution" name="OPT_ID_1435"><span class="sb_authors aug" name="OPT_ID_1436"><span class="sb_author au" name="OPT_ID_1437"><span class="ce_given-name fnm" name="OPT_ID_1438">L.N.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1439">Wang</span></span><span class="x"> and </span><span class="sb_author au" name="OPT_ID_1440"><span class="ce_given-name fnm" name="OPT_ID_1441">J.M.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1442">Li</span></span><span class="x">, </span></span><span class="sb_title atl" name="OPT_ID_1443"><span class="sb_maintitle" name="OPT_ID_1444">Evaluation of immunoglobulin M and G Western blot and ELISA for screening antibodies to <span class="ce_italic" name="OPT_ID_1445">Treponema pallidum</span> in blood donors</span><span class="x">, </span></span>
                        </span><span class="sb_host" name="OPT_ID_1446"><span class="sb_issue" name="OPT_ID_1447"><span class="sb_series" name="OPT_ID_1448"><span class="sb_title sitl" name="OPT_ID_1449"><span class="sb_maintitle" name="OPT_ID_1450">Sex Transm Dis</span></span><span class="x">&#160;</span><span class="sb_volume-nr vol" name="OPT_ID_1451">36</span><span class="x">&#160;</span></span><span class="sb_issue-nr iss" name="OPT_ID_1452"><span class="x">(</span>7<span class="x">), </span></span><span class="sb_date date" name="OPT_ID_1453">2009</span><span class="x">, </span></span><span class="sb_pages pages" name="OPT_ID_1454"><span class="sb_first-page fpage" name="OPT_ID_1455">413</span><span class="sb_last-page lpage" name="OPT_ID_1456"><span class="x">&#8211;</span>416</span>
                        </span>
                        </span><span class="x">.</span></span>
                    </div>
                    <div class="ce_bib-reference" id="bib16" name="OPT_ID_1457"><span class="ce_label" name="OPT_ID_1458">16</span><span class="x">.&#160;</span><span class="sb_reference" name="OPT_ID_1459"><span class="sb_contribution" name="OPT_ID_1460"><span class="sb_authors aug" name="OPT_ID_1461"><span class="sb_author au" name="OPT_ID_1462"><span class="ce_given-name fnm" name="OPT_ID_1463">K.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1464">Linnet</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1465"><span class="ce_given-name fnm" name="OPT_ID_1466">P.M.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1467">Bossuyt</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1468"><span class="ce_given-name fnm" name="OPT_ID_1469">K.G.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1470">Moons</span></span><span class="x"> and </span><span class="sb_author au" name="OPT_ID_1471"><span class="ce_given-name fnm" name="OPT_ID_1472">J.B.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1473">Reitsma</span></span><span class="x">, </span></span><span class="sb_title atl" name="OPT_ID_1474"><span class="sb_maintitle" name="OPT_ID_1475">Quantifying the accuracy of a diagnostic test or marker</span><span class="x">, </span></span>
                        </span><span class="sb_host" name="OPT_ID_1476"><span class="sb_issue" name="OPT_ID_1477"><span class="sb_series" name="OPT_ID_1478"><span class="sb_title sitl" name="OPT_ID_1479"><span class="sb_maintitle" name="OPT_ID_1480">Clin Chem</span></span><span class="x">&#160;</span><span class="sb_volume-nr vol" name="OPT_ID_1481">58</span><span class="x">&#160;</span></span><span class="sb_issue-nr iss" name="OPT_ID_1482"><span class="x">(</span>9<span class="x">), </span></span><span class="sb_date date" name="OPT_ID_1483">2012</span><span class="x">, </span></span><span class="sb_pages pages" name="OPT_ID_1484"><span class="sb_first-page fpage" name="OPT_ID_1485">1292</span><span class="sb_last-page lpage" name="OPT_ID_1486"><span class="x">&#8211;</span>1301</span>
                        </span>
                        </span><span class="x">.</span></span>
                    </div>
                    <div class="ce_bib-reference" id="bib17" name="OPT_ID_1487"><span class="ce_label" name="OPT_ID_1488">17</span><span class="x">.&#160;</span><span class="sb_reference" name="OPT_ID_1489"><span class="sb_contribution" name="OPT_ID_1490"><span class="sb_authors aug" name="OPT_ID_1491"><span class="sb_author au" name="OPT_ID_1492"><span class="ce_given-name fnm" name="OPT_ID_1493">E.C.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1494">Tramont</span></span><span class="x">, </span></span><span class="sb_title atl" name="OPT_ID_1495"><span class="sb_maintitle" name="OPT_ID_1496"><span class="ce_italic" name="OPT_ID_1497">Treponema pallidum</span> (Syphilis)</span><span class="x">, </span></span>
                        </span><span class="sb_host" name="OPT_ID_1498"><span class="sb_edited-book" name="OPT_ID_1499"><span class="x">In: </span><span class="sb_editors eds" name="OPT_ID_1500"><span class="sb_editor ed" name="OPT_ID_1501"><span class="ce_given-name fnm" name="OPT_ID_1502">G.L.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1503">Mandell</span></span><span class="x">, </span><span class="sb_editor ed" name="OPT_ID_1504"><span class="ce_given-name fnm" name="OPT_ID_1505">J.E.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1506">Bennett</span></span><span class="x"> and </span><span class="sb_editor ed" name="OPT_ID_1507"><span class="ce_given-name fnm" name="OPT_ID_1508">R.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1509">Dolin</span></span><span class="x">, </span></span><span class="x">(Eds.), </span><span class="sb_title ebtl" name="OPT_ID_1510"><span class="sb_maintitle" name="OPT_ID_1511">Principles and practice of infectious diseases</span><span class="x">, </span></span><span class="sb_edition" name="OPT_ID_1512"><span class="x">&#160;</span>6th ed<span class="x">, </span></span><span class="sb_date date" name="OPT_ID_1513">2005</span><span class="x">, </span><span class="sb_publisher" name="OPT_ID_1514"><span class="sb_name" name="OPT_ID_1515">Elsevier<span class="x">; </span></span><span class="sb_location" name="OPT_ID_1516">Philadelphia<span class="x">, </span></span>
                        </span>
                        </span><span class="sb_pages pages" name="OPT_ID_1517"><span class="sb_first-page fpage" name="OPT_ID_1518">2768</span><span class="sb_last-page lpage" name="OPT_ID_1519"><span class="x">&#8211;</span>2785</span>
                        </span>
                        </span><span class="x">.</span></span>
                    </div>
                    <div class="ce_bib-reference" id="bib18" name="OPT_ID_1520"><span class="ce_label" name="OPT_ID_1521">18</span><span class="x">.&#160;</span><span class="sb_reference" name="OPT_ID_1522"><span class="sb_contribution" name="OPT_ID_1523"><span class="sb_authors aug" name="OPT_ID_1524"><span class="sb_author au" name="OPT_ID_1525"><span class="ce_given-name fnm" name="OPT_ID_1526">L.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1527">Creegan</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1528"><span class="ce_given-name fnm" name="OPT_ID_1529">H.M.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1530">Bauer</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1531"><span class="ce_given-name fnm" name="OPT_ID_1532">M.C.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1533">Samuel</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1534"><span class="ce_given-name fnm" name="OPT_ID_1535">J.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1536">Klausner</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1537"><span class="ce_given-name fnm" name="OPT_ID_1538">S.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1539">Liska</span></span><span class="x"> and </span><span class="sb_author au" name="OPT_ID_1540"><span class="ce_given-name fnm" name="OPT_ID_1541">G.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1542">Bolan</span></span><span class="x">, </span></span><span class="sb_title atl" name="OPT_ID_1543"><span class="sb_maintitle" name="OPT_ID_1544">An evaluation of the relative sensitivities of the venereal disease research laboratory test and the <span class="ce_italic" name="OPT_ID_1545">Treponema pallidum</span> particle agglutination test among patients diagnosed with primary syphilis</span><span class="x">, </span></span>
                        </span><span class="sb_host" name="OPT_ID_1546"><span class="sb_issue" name="OPT_ID_1547"><span class="sb_series" name="OPT_ID_1548"><span class="sb_title sitl" name="OPT_ID_1549"><span class="sb_maintitle" name="OPT_ID_1550">Sex Transm Dis</span></span><span class="x">&#160;</span><span class="sb_volume-nr vol" name="OPT_ID_1551">34</span><span class="x">&#160;</span></span><span class="sb_issue-nr iss" name="OPT_ID_1552"><span class="x">(</span>12<span class="x">), </span></span><span class="sb_date date" name="OPT_ID_1553">2007</span><span class="x">, </span></span><span class="sb_pages pages" name="OPT_ID_1554"><span class="sb_first-page fpage" name="OPT_ID_1555">1016</span><span class="sb_last-page lpage" name="OPT_ID_1556"><span class="x">&#8211;</span>1018</span>
                        </span>
                        </span><span class="x">.</span></span>
                    </div>
                    <div class="ce_bib-reference" id="bib19" name="OPT_ID_1557"><span class="ce_label" name="OPT_ID_1558">19</span><span class="x">.&#160;</span><span class="sb_reference" name="OPT_ID_1559"><span class="sb_contribution" name="OPT_ID_1560"><span class="sb_authors aug" name="OPT_ID_1561"><span class="sb_author au" name="OPT_ID_1562"><span class="ce_given-name fnm" name="OPT_ID_1563">M.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1564">Janier</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1565"><span class="ce_given-name fnm" name="OPT_ID_1566">C.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1567">Chastang</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1568"><span class="ce_given-name fnm" name="OPT_ID_1569">E.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1570">Spindler</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1571"><span class="ce_given-name fnm" name="OPT_ID_1572">S.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1573">Strazzi</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1574"><span class="ce_given-name fnm" name="OPT_ID_1575">C.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1576">Rabian</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1577"><span class="ce_given-name fnm" name="OPT_ID_1578">A.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1579">Marcelli</span></span><span class="x">, </span><span class="sb_et-al" name="OPT_ID_1580"><span class="x"> et&#160;al., </span></span>
                        </span><span class="sb_title atl" name="OPT_ID_1581"><span class="sb_maintitle" name="OPT_ID_1582">A prospective study of the influence of HIV status on the seroreversion of serological tests for syphilis</span><span class="x">, </span></span>
                        </span><span class="sb_host" name="OPT_ID_1583"><span class="sb_issue" name="OPT_ID_1584"><span class="sb_series" name="OPT_ID_1585"><span class="sb_title sitl" name="OPT_ID_1586"><span class="sb_maintitle" name="OPT_ID_1587">Dermatology</span></span><span class="x">&#160;</span><span class="sb_volume-nr vol" name="OPT_ID_1588">198</span><span class="x">&#160;</span></span><span class="sb_issue-nr iss" name="OPT_ID_1589"><span class="x">(</span>4<span class="x">), </span></span><span class="sb_date date" name="OPT_ID_1590">1999</span><span class="x">, </span></span><span class="sb_pages pages" name="OPT_ID_1591"><span class="sb_first-page fpage" name="OPT_ID_1592">362</span><span class="sb_last-page lpage" name="OPT_ID_1593"><span class="x">&#8211;</span>369</span>
                        </span>
                        </span><span class="x">.</span></span>
                    </div>
                    <div class="ce_bib-reference" id="bib20" name="OPT_ID_1594"><span class="ce_label" name="OPT_ID_1595">20</span><span class="x">.&#160;</span><span class="sb_reference" name="OPT_ID_1596"><span class="sb_contribution" name="OPT_ID_1597"><span class="sb_authors aug" name="OPT_ID_1598"><span class="sb_author au" name="OPT_ID_1599"><span class="ce_given-name fnm" name="OPT_ID_1600">A.C.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1601">Sena</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1602"><span class="ce_given-name fnm" name="OPT_ID_1603">B.L.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1604">White</span></span><span class="x"> and </span><span class="sb_author au" name="OPT_ID_1605"><span class="ce_given-name fnm" name="OPT_ID_1606">P.F.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1607">Sparling</span></span><span class="x">, </span></span><span class="sb_title atl" name="OPT_ID_1608"><span class="sb_maintitle" name="OPT_ID_1609">Novel <span class="ce_italic" name="OPT_ID_1610">Treponema pallidum</span> serologic tests: a paradigm shift in syphilis screening for the 21st century</span><span class="x">, </span></span>
                        </span><span class="sb_host" name="OPT_ID_1611"><span class="sb_issue" name="OPT_ID_1612"><span class="sb_series" name="OPT_ID_1613"><span class="sb_title sitl" name="OPT_ID_1614"><span class="sb_maintitle" name="OPT_ID_1615">Clin Infect Dis</span></span><span class="x">&#160;</span><span class="sb_volume-nr vol" name="OPT_ID_1616">51</span><span class="x">&#160;</span></span><span class="sb_issue-nr iss" name="OPT_ID_1617"><span class="x">(</span>6<span class="x">), </span></span><span class="sb_date date" name="OPT_ID_1618">2010</span><span class="x">, </span></span><span class="sb_pages pages" name="OPT_ID_1619"><span class="sb_first-page fpage" name="OPT_ID_1620">700</span><span class="sb_last-page lpage" name="OPT_ID_1621"><span class="x">&#8211;</span>708</span>
                        </span>
                        </span><span class="x">.</span></span>
                    </div>
                    <div class="ce_bib-reference" id="bib21" name="OPT_ID_1622"><span class="ce_label" name="OPT_ID_1623">21</span><span class="x">.&#160;</span><span class="sb_reference" name="OPT_ID_1624"><span class="sb_contribution" name="OPT_ID_1625"><span class="sb_authors aug" name="OPT_ID_1626"><span class="sb_author au" name="OPT_ID_1627"><span class="ce_given-name fnm" name="OPT_ID_1628">A.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1629">McMillan</span></span><span class="x"> and </span><span class="sb_author au" name="OPT_ID_1630"><span class="ce_given-name fnm" name="OPT_ID_1631">H.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1632">Young</span></span><span class="x">, </span></span><span class="sb_title atl" name="OPT_ID_1633"><span class="sb_maintitle" name="OPT_ID_1634">Reactivity in the Venereal Diseases Research Laboratory test and the Mercia IgM enzyme immunoassay after treatment of early syphilis</span><span class="x">, </span></span>
                        </span><span class="sb_host" name="OPT_ID_1635"><span class="sb_issue" name="OPT_ID_1636"><span class="sb_series" name="OPT_ID_1637"><span class="sb_title sitl" name="OPT_ID_1638"><span class="sb_maintitle" name="OPT_ID_1639">Int J STD AIDS</span></span><span class="x">&#160;</span><span class="sb_volume-nr vol" name="OPT_ID_1640">19</span><span class="x">&#160;</span></span><span class="sb_issue-nr iss" name="OPT_ID_1641"><span class="x">(</span>10<span class="x">), </span></span><span class="sb_date date" name="OPT_ID_1642">2008</span><span class="x">, </span></span><span class="sb_pages pages" name="OPT_ID_1643"><span class="sb_first-page fpage" name="OPT_ID_1644">689</span><span class="sb_last-page lpage" name="OPT_ID_1645"><span class="x">&#8211;</span>693</span>
                        </span>
                        </span><span class="x">.</span></span>
                    </div>
                    <div class="ce_bib-reference" id="bib22" name="OPT_ID_1646"><span class="ce_label" name="OPT_ID_1647">22</span><span class="x">.&#160;</span><span class="sb_reference" name="OPT_ID_1648"><span class="sb_contribution" name="OPT_ID_1649"><span class="sb_authors aug" name="OPT_ID_1650"><span class="sb_author au" name="OPT_ID_1651"><span class="ce_given-name fnm" name="OPT_ID_1652">J.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1653">Rotty</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1654"><span class="ce_given-name fnm" name="OPT_ID_1655">D.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1656">Anderson</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1657"><span class="ce_given-name fnm" name="OPT_ID_1658">M.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1659">Garcia</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1660"><span class="ce_given-name fnm" name="OPT_ID_1661">J.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1662">Diaz</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1663"><span class="ce_given-name fnm" name="OPT_ID_1664">S.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1665">Van de Waarsenburg</span></span><span class="x">, </span><span class="sb_author au" name="OPT_ID_1666"><span class="ce_given-name fnm" name="OPT_ID_1667">T.</span><span class="x"> </span><span class="ce_surname snm" name="OPT_ID_1668">Howard</span></span><span class="x">, </span><span class="sb_et-al" name="OPT_ID_1669"><span class="x"> et&#160;al., </span></span>
                        </span><span class="sb_title atl" name="OPT_ID_1670"><span class="sb_maintitle" name="OPT_ID_1671">Preliminary assessment of <span class="ce_italic" name="OPT_ID_1672">Treponema pallidum</span>-specific IgM antibody detection and a new rapid point-of-care assay for the diagnosis of syphilis in human immunodeficiency virus-1-infected patients</span><span class="x">, </span></span>
                        </span><span class="sb_host" name="OPT_ID_1673"><span class="sb_issue" name="OPT_ID_1674"><span class="sb_series" name="OPT_ID_1675"><span class="sb_title sitl" name="OPT_ID_1676"><span class="sb_maintitle" name="OPT_ID_1677">Int J STD AIDS</span></span><span class="x">&#160;</span><span class="sb_volume-nr vol" name="OPT_ID_1678">21</span><span class="x">&#160;</span></span><span class="sb_issue-nr iss" name="OPT_ID_1679"><span class="x">(</span>11<span class="x">), </span></span><span class="sb_date date" name="OPT_ID_1680">2010</span><span class="x">, </span></span><span class="sb_pages pages" name="OPT_ID_1681"><span class="sb_first-page fpage" name="OPT_ID_1682">758</span><span class="sb_last-page lpage" name="OPT_ID_1683"><span class="x">&#8211;</span>764</span>
                        </span>
                        </span><span class="x">.</span></span>
                    </div>
                </div>
            </div>
        </div>
    </div>
    <div xmlns="" id="toc" class="toc  hide">
        <li name="1" id="OPT_ID_999">Acknowledgements</li>
        <li name="1" id="OPT_ID_834">Introduction</li>
        <li name="2" id="OPT_ID_864">Materials and methods</li>
        <li name="2.1" id="OPT_ID_866">Study design</li>
        <li name="2.2" id="OPT_ID_881">Patient characteristics</li>
        <li name="2.3" id="OPT_ID_892">Serological testing</li>
        <li name="2.4" id="OPT_ID_903">Statistical analysis</li>
        <li name="3" id="OPT_ID_911">Results</li>
        <li name="4" id="OPT_ID_945">Discussion</li>
        <li name="5" id="OPT_IDaa_993">Addendum</li>
        <li name="6" id="OPT_ID_996">Conflict of interest</li>
        <li name="1" id="OPT_ID_1003">References</li>
    </div>
</body>

</html>
